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Introduction 
 
Glycosaminoglycans (GAGs) are natural polysaccharides ubiquitously distributed on cell 
membranes and in the extracellular matrix (ECM) of all animal organisms. Owing to their 
peculiar chemical structure, GAGs bind to several proteins and cell signaling factors in 
cell environment, thus being involved in many physiological and pathological processes 
[1, 2]. As result, they find application in pharmaceutical field as both therapeutic agents 
and targeting molecules in drug delivery. 
According to the type of the constituent monosaccharides and the substitution degree, 
GAGs are classified into four broad groups [2]. They are acidic linear polymers composed 
of many repeating disaccharide units of hexosamine and uronic acid, with the exception 
of keratan sulfate which contains galactose instead of uronic acid [3]. Keratan sulfate 
(KS) has less variable primary structure compared to other sulfated GAGs. Its basic 
repeating unit is made of N-acetyl-glucosamine linked (β 1→3) to a galactose residue. 
Sulfation may occur in position 6 of both moieties and non-sulfated, mono-sulfated and 
di-sulfated disaccharides alternate along KS chain [4]. 
KS is a component of ECM of cartilages, bone and cornea, where it acts as signaling and 
hydrating agent. Like other GAGs, it is involved in several physiopathological conditions 
and its possible use as therapeutic or target agent is gaining interest in pharmaceutical 
field [4]. As an example, since it was found that KS-deficiency makes the mice cartilage 
more fragile, the administration of hexogen KS was suggested as a novel strategy for the 
treatment of human inflammatory diseases, such as rheumatoid arthritis and osteoarthritis 
[5].  
Chondroitin sulfate (CS) and dermatan sulfate (DS) (also known as chondroitin sulfate 
B) have a common chemical precursor, the chondroitin, which consists of uronic acid 
linked (β 1→3) to N-acetyl-galactosamine. For this feature, they are more properly 
defined as “galactosaminoglycans” [6]. The disaccharide unit can be un-, mono- or di-
sulfated. DS contains uronic acid in two epimeric forms, namely glucuronic and iduronic 
acids, whereas the uronic acid residues of chondroitin sulfate are all glucuronic acids [7]. 
CS and DS have numerous potential therapeutic applications but, as matter of fact, their 
clinical administration is limited [8]. DS preparations have been used for the prophylaxis 
and treatment of venous thromboembolism, disseminated intravascular coagulation 
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syndrome and for the prevention of deep vein thrombosis in patients with hip fracture. 
CS is indicated for the treatment of osteoarthritis [9].  
Heparin (UFH) and heparan sulfate (HS) are the sulfated GAGs that present the most 
complex structure. They are a mixture of polysaccharide chains of different length and 
degree of substitution having as monomeric unit a glucosamine linked through 1,4 
glycosidic linkage to an iduronic or glucuronic acid [10]. The glucosamine may be either 
sulfated or acetylated and each disaccharide may have up to three functional groups 
sulfated, thus resulting in a huge number of possible combinations, among which the most 
frequent is the trisulfated disaccharide having the glucosamine sulfated at the amino 
group and at the carbon in position 6, and the iduronic acid sulfated in position 2. With 
respect to UFH, HS exhibits a lower content of iduronic acid, lower degree of sulfation 
and an increased percentage of N-acetyl glucosamine (up to 10%) [6, 11]. The presence 
of heterogeneous regions on UFH/HS chains is the basis of their therapeutic value, which 
relies on the ability to bind to a variety of proteins (chemokines, growth and coagulation 
factors, metalloproteinase, low-density lipoproteins, adhesion proteins and many others, 
up to 100 different proteins), modulating their biological activity [2, 12]. Despite of the 
wide range of effects, UFH/HS are mainly known for their widespread use as 
anticoagulant and antithrombotic agents. Nowadays, the use of UFH is restricted to the 
hospital and low molecular weight heparins (LMWHs), obtained by different 
depolymerization methods of UFH, have replaced its use in outpatients due to the 
improved pharmacokinetic and pharmacodynamic [13]. LMWHs ideally share the same 
basic chemical structure of UFH but present peculiar terminal end residues which are 
artifacts of the specific production method (for further reading see [14] (chapter 4)). 
Hyaluronic acid (frequently referred as hyaluronan because of its polyanion form) is the 
only un-sulfated polysaccharide of the class and it has the widest distribution of molecular 
weight (Mw). In fact, in a completed hyaluronan molecule up to 10,000 repeating units 
can be found with a molecular mass ranging from 500 to millions of Daltons [15]. HA 
doesn’t show the sequence variability typical of the other GAGs. Indeed, it has a unique 
basic disaccharide unit consisting of N-acetyl-glucosamine and D-glucuronic acid. 
However, it presents a complex secondary structure since it can crystallize in several 
helical forms which symmetry is influenced by pH, humidity and type of counter-ion [7]. 
HA counts the largest number of applications both in medical and in cosmetic field. It is 
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used for the treatment of osteoarthritis, for cutaneous wound healing, as biomaterial for 
bioengineering purposes and filler in dermatologic surgery. Moreover, HA is a well 
known moisturizing agent and free radical scavenger commonly used in cosmetic 
formulations [16, 17]. 
50% of the total amount of HA present in the body is localized in the extracellular matrix 
of the skin where it plays a key role in maintaining skin homeostasis. Hence, its topical 
application is useful for the treatment of some skin disorders and HA based products are 
available on the market for skin care [18, 19]. GAGs in general and in particular HA, 
resulted also to be able to enhance the delivery of other drugs into the skin and this 
observation led to the development of a topical formulation (Solaraze®) containing 
diclofenac in HA gel, approved in many countries for the treatment of actinic keratoses 
[16].  
Transdermal/dermal delivery of such polysaccharides may also represent a non invasive, 
challenging alternative to the conventional routes for their therapeutic administration 
since it allows to improve patient compliance, minimize side effects and obtain a 
sustained release of drug with possibility to reach either a local or a systemic effect [20].  
Altogether, GAGs are highly hydrophilic polyanionic macromolecules characterized by 
large molecular size. In solution, many H-bonds are formed (in addition to those already 
present between neighboring disaccharide units) and a large hydrodynamic volume is 
occupied as result of the repulsion between charged groups [6, 16]. Hence, they do not 
exhibit the suitable properties to cross the outer layer of the skin, the stratum corneum 
(SC), which, with its brick and mortar structure, represents the rate-limiting barrier to skin 
permeation. 
The study of the diffusion features of GAGs is further complicated by their intrinsic 
heterogeneity in terms of both chemical structure and conformational behavior. Indeed, 
in the solid state, GAGs chains fold into helices of different periodicity and in solution 
the flexibility of some glycosidic linkages produces numerous conformations, which 
coexist in equilibrium [3]. 
Nevertheless, polysaccharides have been incorporated in topical formulations for 
different purposes. The use of topical UFH to treat the symptoms of peripheral vascular 
disorders is well-established in Europe [21] and, as already stated, creams and gels 
containing HA are available on the market. 
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However, the diffusion of these polymers through human skin has been relatively poor 
investigated and contrasting data are reported in literature. 
As far as HA is concerned, Brown and coworkers, after application in vivo of radiolabeled 
HA, found that it was able to cross the skin barrier reaching the dermis in significant 
amount and that the permeation of HA was not limited to its small fractions [22]. More 
recently, in vitro studies carried out by using hairless mice skin evidenced a slow diffusion 
even of HA tetrasaccharides and confirmed the limiting effect of SC, since the flux 
resulted to be significantly increased through SC-stripped skin [23].  
More extensive and documented research has been focused on heparins (both UFH and 
LMWHs). Experimental results evidenced a poor passive permeation of these molecules 
through the skin and the need of an enhancement strategy to improve their flux. Several 
physical and chemical techniques have been investigated for this purpose [24].  
In particular, different methods of perturbation or disruption of SC have been exploited 
[25-30].  
Pacini et al., by using the approved device Transderm®, revealed that iontophoresis have 
a limited effect on the diffusion of UFH and preferentially enhances the permeation of 
low molecular weight fractions, suggesting the application of this system for the skin 
delivery of LMWHs [27]. In contrast, Le and coworkers found an increase of 10-fold of 
the immediate flux of UFH using iontophoresis and a 13-fold increase of long-term flux 
after application of ultrasounds [28]. In another study, the pretreatment of the skin with 
low-frequency ultrasounds improved the in vitro flux of radiolabeled UFH of 21-fold and 
allowed a sustained delivery of biologically active dalteparin in vivo [29]. On the contrary, 
in in vitro studies performing using hairless rat skin, the flux of LMWHs was found to be 
almost negligible after application of both iontophoresis and ultrasound (0.065 and 0.058 
IU/cm2h) [30].  
 
This Ph.D was aimed to clarify which aspects rule the human skin permeability of the 
different classes of GAGs to assess the real feasibility of transdermal/dermal delivery of 
these macromolecules. In particular, the research activity was focused on HA and 
heparins, the two GAGs most employed as both active compounds and drug carriers.  
The experimental work was articulated in two main steps:  
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1) the investigation of the influence of the main structural features (sequence, Mw, 
polarity, and conformational behavior) on the percutaneous absorption of HA and 
heparins (UFH and LMWHs), to point out which structural components play a key role 
in the diffusion through the skin;  
2) the fine-tuning of a suitable strategy to improve the permeation of heparins through 
human skin by using peptides as skin penetration enhancers. 
Indeed, although several physical enhancement techniques have been applied (even 
successfully) to the skin delivery of heparins, any approach resulted to be conclusive and 
free of concerns. Strategies based on the abrasion or disruption of SC cannot be managed 
by patients on their own and, altogether, the available data reveal that a combination of 
methods is preferred to reach a suitable therapeutic effect. To achieve this goal the 
development of complex devices is required and this may limit the administration to 
outpatients [24]. On the other hand, the use of chemical enhancers such as Azone® is 
limited by the toxic and skin irritant potential at certain doses [31]. 
A novel alternative, which has gained interest in the last years and has not been 
investigated for this class of macromolecules, is the use of “cell-penetrating peptides 
(CPPs)” which penetrate, without damaging, the biological membranes at low 
concentration and with high efficiency. A particular class of these peptides are the so 
called “skin penetrating peptides” which resulted to be able to enhance the diffusion 
through the skin of biologic active compounds chemically bound to them (through 
covalent linkage or electrostatic interaction) [32].  
After translocation across the membrane, the drug can be released or directly exerts its 
action as complex with the peptide. Some of these peptides demonstrated to be also 
effective without requiring a direct conjugation to the active molecule. As an example, a 
23-aminoacid peptide, magainin, by electrostatic interaction with negatively charged 
lipids of SC, seemed to induce pore formation within lipid bilayers, causing a leakage of 
the tight barrier and allowing the diffusion of the free drug across it [33]. Phage display 
is a biotechnological technique which uses phages as expression vectors and which can 
be exploited to screen skin penetrating peptides for dermal and transdermal delivery. 
Phages tolerate the fusion of exogenous amino acid sequence to the genes codifying for 
capside’s proteins, without undergoing a loss of functionality. A hybrid fusion protein is 
formed which is expressed on the outer surface of the phage. Hence, by using a phage 
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display library, it is possible to screen simultaneously different peptide sequences for the 
desired function [34]. TD-1 was the first peptide specifically identified by in vivo phage 
display (on mouse skin) which allowed the systemic absorption of macromolecules 
applied topically on the skin. To date, TD-1, along with SPACE peptide studied for the 
delivery of siRNA, is the only skin penetrating peptide found to improve specifically the 
transdermal delivery of macromolecules [35].  
In this work phage display was used to identify a skin penetrating peptide able to deliver 
heparins into human skin. The Ph.D.-7 Phage Display Peptide Library based on the 
filamentous phage M13 was used and the experiments were carried out in a vertical Franz 
diffusion apparatus using human SCE as membrane. 
 
 
 
During my Ph.D program I also had the opportunity to spend 8 months as visiting student 
at the Institut Galien Paris-Sud (Université Paris-Sud 11, Châtenay-Malabry, France) 
where I gained experience in nano-carriers formulation as well as in cell biology and cell 
culture. In fact, I was involved in a research project which dealt with the development of 
liposomes encapsulating a new inhibitor of heat shock protein 90 (Hsp90), 6BrCaQ, for 
the delivery of the drug to prostate and breast cancer cells. Hsp90 is a molecular 
chaperone that modulates the biological activity of several oncoproteins, being 
overexpressed in many types of cancer [36]. Although 6BrCaQ demonstrated a promising 
cytotoxic effect against different cancer cell lines in vitro, its therapeutic use is limited by 
its low water solubility that prevents both the full characterization of the biological 
activity in vivo and the intravenous administration [37]. To overcome this drawback, in 
this work the drug was encapsulated in liposomes with a dual purpose: to allow the drug 
solubilization through its distribution in the lipid bilayer and to exploit the ability of 
liposomal carriers to target cancer. Indeed liposomes, as long as they have certain features 
(nano-sized dimensions and Stealth® properties), can passively accumulate in solid 
tumors through the enhanced and retention permeability effect (EPR), improving the 
bioavailability of the drug at the target site and limiting the exposure of health tissues to 
the cytotoxic agent [38]. Moreover, they can be internalized into the cells thus 
potentiating the action of the free drug [39].  
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Stealth® liposomes were formulated by the conventional thin film hydration method and 
characterized in terms of size, zeta potential, physical stability and drug leakage. The 
effect of the encapsulated drug on the tumor growth was evaluated in cell culture in vitro 
using metastatic prostate and breast cancer cell lines. The results of this experimental 
work are reported in the Appendix of this thesis. 
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Abstract 
 
The data reported in literature suggest the capacity of biomacromolecules to permeate the 
human skin even though such a transdermal permeation appears to be governed by 
physicochemical parameters which are significantly different compared to those ruling 
the skin permeation of small molecules. On these grounds, the present study was 
undertaken to investigate the in vitro diffusion properties through the human epidermis 
of hyaluronic acid and their sulfates. Low- and medium-molecular weight hyaluronic 
acids and the corresponding derivatives at two degrees of sulfation were then tested. In 
vitro studies evidenced that the sulfated polymers permeate better than the corresponding 
hyaluronic acid, despite their vastly greater polarity, while the observed permeation 
markedly decreases when increasing the polymer’s molecular weight regardless of the 
sulfation degree. Using a fluorescent-labeled polysaccharide, it was also evidenced that 
hyaluronans have a great affinity for corneocytes and likely cross the stratum corneum 
mainly through a transcellular route. The molecular dynamics study revealed how the 
observed permeations for the investigated polysaccharides can be rationalized by 
monitoring their conformational profiles since the permeation was found to be directly 
related to their capacity to assume extended and flexible conformations  
 
 
 
 
 
 
 
 
 
 
The content of this chapter was published in Chemistry & Biodiversity (Cilurzo et al. Chemistry 
& Biodiversity 2014, 11 (4), 551-561) 
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1.1 Introduction 
 
Transdermal administration is a well-established and attractive route of administration. 
However, the absorption of a drug applied on the skin is limited by the stratum corneum, 
which presents a multi-layered wall-like structure in which flat keratinized corneocytes 
are embedded in a lipophilic network of ceramides, cholesterol esters and fatty acids. The 
barrier properties of this dense layer were investigated in-depth, revealing that 
lipophilicity and molecular size play key roles in determining the transdermal permeation 
of small molecules [1; 2].  
Conversely, the transdermal permeation of biological drugs was scantly investigated, 
even though it is commonly accepted that their passive diffusion is limited by both large 
molecular volume and ability to elicit H-bonds. However, polysaccharides have been 
successfully and widely applied through the skin, even though very little data on their 
permeation process has been hitherto reported in literature.  
Thus, very few and often contrasting studies are reported for heparin [3], heparinoids [4], 
chondroitin [3] and hyaluronic acid (also called hyaluronan; HA). As an example, HA 
was reported to be unable to penetrate the stratum corneum in in vitro experiments due to 
its high hydrophilicity and stiffened random-coil molecular configuration [5; 6]. In 
another study performed in vivo by applying a gel loaded by 3% w/w radiolabelled HA 
to human forearm, it was able to penetrate into the skin reaching the dermis within 30 
min [7]. 
Aiming to elucidate the penetration mechanism of HA through human epidermis, the 
present work is focused on the impact of molecular weight, conformation and polarity on 
the diffusion process of polysaccharides using low- and medium-molecular weight HA 
and the corresponding derivatives at different degree of sulfation (HAS). Besides their 
relevant physicochemical profiles, these biomacromolecules were chosen for their 
significant impact in the biomedical field, since they are widely used as hydration agents, 
free radical scavengers [8] and skin penetration enhancers [9]. 
The transdermal penetration of HAs was experimentally determined by the Franz 
diffusion cell method using human epidermis as a membrane and confirmed by using 
confocal laser scanner microscopy (CLSM), while the possible relationship between the 
polymer’s conformation and the ability to permeate the human epidermis was studied in 
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silico by molecular dynamics (MD) simulations. Indeed, despite its relevance in living 
organisms and artificial biosystems, the conformational properties of the HAs have been 
scantly investigated at an atomic level [10]. The hitherto reported computational studies 
have involved only very short oligomers [11], and the effects of sulfonation on the 
conformation of HA have never been analyzed by MD simulations. 
 
1.2 Experimental Part 
 
1.2.1 Chemicals 
 
All tested Hyaluronic acids (Has) were kindly provided by Fidia Farmaceutici (Italy). As 
summarized in Table 1.1, the study involved six different HAs including both sulfated 
(HAS) and nonsulfated (HA) polymers differing for the molecular weight (low molecular 
weight, about 6.5 kDa, and medium molecular weight, about 185 kDa) and for the 
sulfation degree (1% and 2.5% mol, respectively). The reported polydispersity indices 
(Table 1.1), which encode for the distribution of polymer’s molecular mass and tend to 
unity for homogenous samples, confirm the satisfactory homogeneity of the tested 
polysaccharide samples. The study also involved a medium molecular weight polymer 
conjugated with fluorescein isothiocyanate (FITC), an aliquot of 1 mg/ml of which 
contained 0.2378 g of fluorescent probe (Fidia Farmaceutici, Italy), hereinafter termed 
HAF for the sake of brevity. At the end of the depolymerization process, the medium 
molecular weight HA was dialyzed against water by using a membrane with a 30 kDa 
molecular weight cut-off (Centricon® Amicon, Millipore, US). The absence of olgomers 
with molecular weight lower than 30 kDa in the dialyzed fractions was assessed by the 
carbazole method [12] which allows the quantification of D-glucuronic acid free units 
produced from the HA hydrolysis. Sodium azide and propidium iodide solution were 
purchased from Sigma Aldrich (Italy). The water used in the experiments was produced 
by a MilliQ® system (Millipore, US). All solvents were of analytic grade, unless 
specified. 
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Table 1.1 – The main characteristics of hyaluronic acids (HA), the corresponding 
derivatives at two degrees of sulfation (HAS) and medium molecular weight HA 
conjugated with fluorescein isothiocyanate (HAF). The relative amounts diffused across 
human stratum corneum and epidermis after 24 hours (Q24) of treatment are also reported 
(mean ± standard deviation, n=3). 
 
 
1.2.2 In vitro permeation studies 
 
The stratum corneum and epidermis used in the permeation studies were obtained from 
the abdominal skin of donors, who underwent cosmetic surgery (30-50 year old, Eurasian 
female). The samples were prepared following the internal standard procedure [13]. The 
full-thickness skin was sealed in evacuated plastic bags and frozen at -20 °C within 24 h 
after removal. Prior to experiments, the skin was thawed at room temperature, and the 
excess of fat was carefully removed. The skin sections were cut into squares of about 2.5 
cm2 and, after immersing the skin in water at 60 °C for 1 min, the epidermis was gently 
separated from the remaining tissue with forceps and carefully inspected by light 
microscopy for any defects.  
Afterwards, the membrane was mounted on the Franz diffusion cell [13], whose receptor 
compartment (volume: 6.0 ml exactly measured) was filled with degassed water 
containing 100 µg/ml NaN3 as preservative. Special care was taken to avoid air bubbles 
between the buffer and the membrane in the receptor compartment. The upper and lower 
parts of the Franz cell were sealed with Parafilm® and fastened together by using a clamp, 
Name 
Substitution 
degree 
(% mol) 
Mw 
(kDa) 
Polydispersity 
Index 
Q24 
(nmol/cm2) 
HA 0 
6.7 1.352 1.0 ±0.6 
170.2 1.596 0.1 ± 0.0 
HAS 
1 
6.8 1.259 4.9 ± 0.8 
181.3 1.483 0.6 ± 0.2 
2.5 
6.4 1.452 2.4 ± 1.0 
200.1 1.390 0.2 ± 0.1 
HAF 0 190.3 1.432 0.1 ± 0.0 
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with the membrane acting as seal between the donor and receptor compartments. The 
system was kept at 37±1 °C with a circulating water bath so that the membrane surface 
temperature was at 32±1 °C throughout the experiments. Before starting experiments, the 
temperature at the surface of each receptor compartment was measured by using a digital 
thermometer (PCE-T390, PCE Corporation, Italy). The donor compartment was filled by 
2% w/w aqueous solution (0.5 ml) and closed. At predetermined times (1, 2, 4, 6, 24 h) 
0.2 ml samples were withdrawn from the receiver compartment and immediately replaced 
with fresh receiver medium. In order to avoid false positive results due to HA eventually 
present in the human skin, control experiments were carried out in parallel using water as 
donor phase. The amount of HA eventually present in the receptor phase was subtracted 
by the sample reading. 
A set of experiments was also carried out to determine the penetration mechanism of HAF 
into the human epidermis. After 0.5, 1, 2, 3, 4 and 24 h, the membranes were dismounted 
from the Franz cells, immediately washed with water and gently stripped by an adhesive 
tape strip (Transpore tape, 3M, US) to remove the un-adsorbed permeant. Then, the 
samples were analyzed by confocal laser scanner microscopy. A permeation experiment 
using a 5 mg/L aqueous solution of FITC as donor phase was also carried out. Sampling 
of receiving phase was carried out after 0.25, 0.5, 1, 2, 3, 4 and 24 h of application.  
All reported values represent the averages of parallel experiments performed in triplicate.  
 
1.2.3 Confocal laser scanner microscopy 
 
The samples of gently stripped membranes were placed on a glass slide with the stratum 
corneum side up, stained by a propidium iodide (PI) solution. Acquisition of fluorescent 
images was performed with a Zeiss LSM 510 confocal microscope (63 objective) with 
sequential acquisition setting at 1024  1024 pixels resolution. Each image was a z series 
projection, with 1 μm interval between each plane. The absence of any cross-talk between 
HAF and PI fluorescence was ensured by a multi-track setting. Three to four sites for 
imaging were randomly selected in each coverslipped section. 
  
Chapter 1 
23 
 
1.2.4 Quantitative determination of HA 
 
The amount of HAS was determined in terms of S content by inductively coupled plasma 
(ICP) MS analysis after depolymerization and mineralisation. The contained Spercentage 
was used to estimate the amount of permeant. The concentration of HA was measured by 
using the carbazole method [12]. In both cases, the permeated amounts were calculated 
by subtracting the amount of S or glucuronic acid determined in the blank. 
HAF was determined by a size exclusion chromatography method (HLPC HP 1100 
Chemstations) using a BioSuiteTM 125 column, 4 μm UHR SEC, 4.6 x 300 mm (Waters, 
US) eluted with 0.1M PBS at pH adjusted to 8 at a flow rate of 0.35 ml/min and 
temperature of 25 °C. The eluent was monitored fluorometrically (excitation 494 nm, 
emission 520 nm; photomultiplier (PMT) gain, 10). Measurements were made with 
injection volume of 100 μl and the retention time of HA was at about 5.8 min. The end of 
the run was determined by injecting FITC (retention time: 17 min). The HAF and FTIC 
contents were determined by using a standard calibration curve ranging from 0.1 to 20 
µg/ml and 0.01 to 5 µg/ml, respectively. 
 
1.2.5 In silico construction of the HA oligomers 
 
The oligomers of HA were generated starting from the 3D structure determined by NMR 
(PDB Id: 2BVK) [14] which is composed by four repeating units (HA4) of β(1→4)-D-
glucuronic acid-β(1→3)-N-acetyl-D-glucosamine (as shown in Figure 1.1) and assumes 
a contracted left-handed four-fold helix geometry. The base HA chain was then obtained 
by multiplying per five the resolved starting structure to generate a molecule composed 
by 20 repeating units (HA20). Two chains of different sulfonation degree were built by 
modifying the base oligomer in the hydroxyl group in 6 of the N-acetyl-D-glucosamine 
residue. Specifically, the two sulfated polymers were constructed by modifying one D-
glucosamine residue every two (HA20S10) and one D-glucosamine residues every four 
(HA20S5). To investigate the effects of molecular length on HA folding, a non-sulfated 
chain composed by 10 repeating units (HA10) was also considered.  
Overall, four HA polymers were simulated: two non-sulfated oligosaccharides of 
different length (HA10 and HA20) and two sulfated oligosaccharides having the same 
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length but differing for the sulfonation degree (HA20S10 and HA20S5). Even though the 
differences in the simulated chains cannot exactly match the differences in the tested 
polysaccharides, and this is clearly due to the fact that short oligomers were here 
simulated, the four simulated polymers can reveal the conformational effect that a HA 
experiences when varying molecular weight and sulfation degree. The conformational 
profile of the generated polymers was analyzed by clustered MonteCarlo procedures (as 
implemented by VEGA suite of programs) [15] which produce 2,000 conformers by 
randomly rotating the flexible bonds pertaining the glycosidic linkages. The so obtained 
lowest energy structures were finally minimized and used in the following MD 
simulations.  
 
 
 
Figure 1.1 – Repeating unit of non-sulfated hyaluronic acid, i.e. (β (1→4)-D-glucuronic acid-β 
(1→3)-N-acetyl-D-glucosamine). Inter- and intra-repeating unit torsions  e  are also indicated.  
 
 
1.2.6 MD simulations 
 
Firstly, the polymers were neutralized by adding the necessary number of sodium ions 
whose pose was computed by SODIUM program [16] and then inserted in a 70 Å × 90 Å 
× 70 Å box of water molecules (apart from HA10 which was solvated by a smaller 50 Å 
× 50 Å × 50 Å water box). It should be noted that, since the initial structure of all 
simulated oligomers corresponds to a rather extended conformation, the considered 
simulation space should be large enough to allow a complete flexibility of the oligomers 
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without biasing constraints. After a preliminary minimization to optimize the relative 
position of waters and ions, the obtained systems underwent 10 ns MD simulations which 
had the following characteristics: (a) Newton's equation was integrated using the r-
RESPA method (every 4 fs for long-range electrostatic forces, 2 fs for short-range non 
bonded forces, and 1 fs for bonded forces); (b) the simulation space was stabilized by 
introducing Periodic Boundary Conditions (75 Å × 100 Å × 75 Å; 55 Å × 55 Å × 55 Å 
for HA10); (c) the long-range electrostatic potential was treated by the Particle Mesh 
Ewald summation method (60 × 90 × 60 grid points; 50 × 50 × 50 points for HA10); (d) 
the temperature was maintained at 300 ± 10 K by means of the Langevin’s algorithm; (e) 
Lennard-Jones (L-J) interactions were calculated with a cut-off of 10 Å and the pair list 
was updated every 20 iterations; (f) a frame was stored every 20 ps, to yield 500 frames. 
The simulations were organized in two phases: an initial period of heating from 0 K to 
300 K over 30,000 iterations (30 ps, i.e. 10 K/ps) and the monitored phase of 10 ns. All 
MD runs were carried out using Namd2.7 [17] with the force-field CHARMm v36 and 
Gasteiger’s atomic charges on a 16-core Tyan VX-50 system. All mentioned 
minimizations were performed using the conjugate gradient algorithm until a r.m.s. equal 
to 0.01 kcal mol-1 Å-1.  
Similarly, HA20 and HA20S5 were simulated in a CHCl3 cluster in order to analyze their 
conformational behavior in an apolar medium which brings to mind the skin’s 
hydrophobic environment. The CHCl3 cluster was built starting from a pair of interacting 
CHCl3 molecules generated by semi-empirical calculations using MOPAC2010 and 
adopting the PM6 level of theory. The initial cubic box (135 Å  135 Å  135 Å, 14075 
molecules) was built by the solvent builder as included in VEGA program and starting 
from the pair of interacting CHCl3 molecules. The obtained system underwent a 
preliminary minimization to optimize the relative position of solvent molecules, and then 
an equilibrating 1 ns MD simulation, which had the above-described characteristics.  Such 
a CHCl3 cluster was then utilized to solvate the HA20 and HA20S10 oligomers, which 
underwent 10 ns MD runs applying the same computational protocol above described for 
the simulations in water. 
The conformational profile of the simulated polymers was analyzed by monitoring the 
two torsion angles, φ and ψ, which describe the glycosidic linkage between two sugar 
units, while the puckering of furanose rings was not considered. As depicted in Figure 
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1.1, the φ angle pertains to the rotatable bond connecting the anomeric carbon atom of ith 
saccharide with glycosidic oxygen atom, while the ψ angle refers to the rotatable bond 
connecting the glycosidic oxygen atom to the carbon atom of i+1th saccharide. 
Specifically, the φ torsion is the dihedral angle defined by the following atoms Hαi- Cαi-
O-Ci+1, while the ψ torsion is defined by Cαi-O-Ci+1-Hi+1. For the sake of simplicity, the 
angle values were analyzed without discriminating between inter- or intra-repeating unit 
torsions. To do this, an ad-hoc script was written for VEGA software which automatically 
recognizes the described torsion angles and can also computes average values when 
analyzing trajectory files. 
 
1.3 Results and Discussion 
 
1.3.1 In vitro penetration studies 
 
Since the sensitivity of the analytic methods permitted to quantify permeants only 24 
hours after application (Table 1.1), it was possible to determine neither the flux of HAs 
through the skin nor the lag time.  
Table 1.1 reports the amounts of the considered HAs diffused across the human stratum 
corneum and epidermis as quantified in the receiving phase after 24 hours and shows that 
molecular weight and sulfation degree strongly influence the permeation of HAs. Thus, 
an analysis in depth of Table 1.1 allows two major considerations to be done. Firstly, the 
comparison of HAs having the same molecular weight but differing for the degrees of 
substitution reveals that the stratum corneum and epidermis were more permeable to the 
sulfated derivatives compared to unsubstituted HA. In detail, the reported permeated 
amounts evidence that the lower substitution degree (i.e. 1% mol) shows favorable skin 
penetration characteristics providing the highest permeated amounts.  
Secondly, the comparison of the three pairs of macromolecules having similar degrees of 
substitution but differing for the molecular weight indicate that the permeated amounts 
of low molecular weight compounds are about 10-folds higher than the corresponding 
medium-molecular weight compounds. Notably, this effect is similarly observed in all 
compared pairs thus suggesting that the molecular weight effect is not influenced by the 
degree of sulfation.  
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1.3.2 Confocal laser scanner microscopy 
 
The penetration pattern of HAs through human stratum corneum and epidermis was then 
estimated using a medium-molecular weight HA conjugated with fluorescein 
isothiocyanate (FITC) as a fluorescent probe, hereinafter termed HAF for the sake of 
brevity.  
The confocal images of untreated stratum corneum and epidermis stained by propidium 
iodide (PI) (red signal) clearly shows corneocytes as well as the nuclei of dead cells of 
epidermis (Fig. 1.2 A). After 30 min exposure to HAF, a green signal appeared in the 
stratum corneum (Fig. 1.2 B) and reached the equilibrium within 2 hours (Fig 1.2 C).  
Fig. 1.3 compares the z-stack projections, namely, the longitudinal views of the 
epidermis, recorded in skin exposed to the HAF solution (Fig. 1.3 A) or a solution 
containing only FITC (Fig. 1.3 B). HAF shows a great affinity for keratins of the stratum 
corneum, since the overall structure of corneocytes presented a homogeneous green 
colorimetry, while it is hardly visible in the epidermis (Fig. 1.3 A). Conversely, the z-
stack projections recorded in the skin samples exposed to the FITC solution evidence only 
a slightly superficial fluorescence (Fig. 1.3 B) remaining constant over time (data not 
shown). 
These results are in agreement with the bio-imaging for the transdermal delivery of FITC 
after topical administration to the dorsal skin of female hairless mice as provided by Yang 
and co-workers [18]. Both results imply that FITC alone is unable to bind any components 
of corneocytes thus indicating that the fluorescent probe diffused through the stratum 
corneum and epidermis without being retained, unlike HA.  
The qualitative results of confocal imaging are consistent with those obtained by gel 
permeation chromatography. Indeed, FITC was quantified in the receptor phase 
(0.02±0.01 µg/cm2) in the first sampling at 15 min, while HAF was detected only after 6 
hours and became quantifiable only after 24 hours (Table 1.1). No other fluorescent 
signals were detected in the chromatograms indicating that HAF permeated without being 
significantly cleaved. This result is also consistent with literature data [7; 18] and allows 
us to confirm that no significant degradation of HA occurred during the passive diffusion 
through stratum corneum and epidermis in our experimental conditions. 
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Fig. 1.2 – CLSM images showing distribution of HAF in human stratum corneum and epidermis 
increasing durations of application: (B) 30 min and (C) 2 h. Panel A depicts the accumulation of 
free propidium iodide in the inter-corneocyte spaces and the nuclei of dead cells of epidermis. 
Being lipophilic in nature, the dye is seen to accumulate in intercellular spaces (red stained). HAF 
appeared in the stratum corneum (green signal) 30 minutes after the application of the solution 
(A) reaching the equilibrium in 2 hours (B). 
 
 
 
 
 
 
Fig. 1.3 – CLSM images (z-stack projections) showing human stratum corneum and epidermis 
30 min after application of (A) HAF and (B) FTIC in aqueous solution. The green fluorescence 
corresponds to furrows where HAF and FTIC accumulated. The red color corresponds from the 
fluorescence emanating from the human stratum corneum and epidermis stained by propidium 
iodide and the yellow-green from HAF.  
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1.3.3 In silico studies of hyaluronans 
 
To analyze the conformational profiles of the simulated hyaluronan chains, three 
descriptors were monitored: (a) the radius of gyration which describes molecular size and 
shape and is well suited to examining polymer flexibility [19]; (b) the end-to-end distance, 
namely the distance between one end of the polymer chain and the other end [20], and (c) 
the percentage of synclinal geometries in the torsions around the anomeric link (φ and ψ, 
as represented in Figure 1.1). The first two descriptors are common indices used in 
polymer simulations, while the last parameter allows the overall structural properties to 
be linked to the local conformational changes in the glycosidic linkages. 
The first part of the study compares the two non-sulfated polymers of different length 
(HA20 and HA10). The reported values for the aforementioned descriptors (Table 1.2) 
show that the two polymers have a comparable conformational profile as suggested by a 
similar abundance of synclinal geometries in both torsions but the longer HA20 chain 
shows a more compacted structure (Fig. 1.4 A) as evidenced by both end-to-end distance 
and radius of gyration normalized per the number of the repeating units. 
These results confirm that in aqueous solution and at low ionic strength hyaluronic acid 
assumes a contracted left-handed helix conformation which is stabilized by an extensive 
H-bond network involving both solute-solvent interactions and inter-residue contacts 
such those seen between the carboxylate of a glucuronic acid and the acetamide of the 
adjacent glucosamine [10]. Such a structure is in encouraging agreement with both NMR 
and X-ray data [14; 21] and emphasizes the conformational versatility of the hyaluronan 
chains despite the caging effect of water molecules around the glycosidic linkages.  
 
 
 
 
 
 
 
 
 
Chapter 1 
30 
 
Table 1.2 – Average values (± standard deviation) for the main parameters extracted from MD 
runs for the non-sulfated HA polymers of different length (HA10 and HA20) and the longest 
sulfated HA polymer at two degrees of sulfation (HA20S5 and HA20s10). The conformations are 
defined as synclinal (in fact including also disfavoured synperiplanar geometries) when 
comprised in the -90 → +90 ranges. In parenthesis, the average values of radius of gyration and 
end-to-end distance normalized per the number of HA units are reported. 
 
 
 
 
Fig. 1.4 – Representative examples of the hyaluronan conformations as extracted by MD runs. 
(A) Folded structure for non-sulfated HA20: the helical structure is characterized by the axis of 
about 1.0 nm a loop diameter of about 1.2 nm and 4 disaccharides per turn. (B) Intermediate 
conformation as obtained for HA20S10 which loses the helical structure while showing a rather 
compact conformation in which the polymer ends fold on themselves forming elliptic structures 
whose shape and width should minimize the electrostatic repulsion between sulfonic groups. (C) 
Extended and flexible structure as observed for HA20S5. 
 
Oligomers 
φ 
% synclinal 
geometries 
ψ 
% synclinal 
geometries 
Radius of 
gyration (Å) 
End-to-end 
distance (Å) 
HA10 60.0 100 
10.32 ± 1.05 
(1.03) 
26.91 ± 4.34 
(2.69) 
HA20 61.5 100 
15.67 ± 8.37 
(0.78) 
25.89 ± 8.57 
(1.29) 
HA20S5 53.8 97.4 
25.92 ± 1.43 
(1.29) 
59.62 ± 6.07 
(2.98) 
HA20S10 64.1 97.8 
21.51 ± 3.88 
(1.08) 
46.67 ± 4.15 
(2.33) 
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The second part of the study involved the sulfated chains with a view to analyzing how 
the sulfonation degree can influence their conformational behavior. Table 1.2 and Fig. 
1.5 compare the longer non-sulfated HA20 chain with the two differently sulfated HA20S5 
and HA20S10 chains which can be seen as representative of the tested hyaluronans at 
medium molecular weight and with a sulfation degree of 1 and 2.5 % mol, respectively. 
The performed MD simulations suggest that both sulfated polymers undergo large 
conformational changes and lose the helical architecture seen in the non-sulfated 
structures. 
Although both sulfated chains show a substantial disruption of the helix motifs, Fig. 1.4 
clearly shows the significant differences between them because the less sulfated HA20S5 
(Fig. 1.4 C) chain appears markedly more extended than the other one (Fig. 1.4 B). This 
is also documented by both end-to-end distance and radius of gyration as well as by 
relative abundance of the synclinal geometries. Concerning the local conformation of the 
glycosidic linkages. Table 1.2 confirms that the ψ angle assumes almost exclusively 
synclinal geometries in all performed simulations regardless of polymer length and 
sulfonation. In contrast, relevant differences are seen in the conformational profiles of the 
φ angle since the percentage of synclinal geometries decreases in the HA20S5 polymer 
which appears characterized by more disordered and more extended conformations (vide 
infra), while the percentage in the HA20S10 chain remains comparable with the values 
observed for the non-sulfated polymers.  
A detailed description of the conformational behavior of the simulated chains is provided 
by the radiuses of gyration (Fig. 1.5 A) and the end-to-end distances (Fig. 1.5 B).  
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Fig. 1.5 – Dynamic profiles of (A) radius of gyration and (B) end-to-end distance as computed 
by MD simulations of non-sulfated HA (HA20, dashed grey line), HA20 at low degree of sulfation 
(HA20S5, black line) and HA20 at high degree of sulfation (HA20S10, grey line). 
 
 
 
Both these descriptors indicate that the HA20S5 polymer assumes significantly extended 
conformations as confirmed by the highest values in both parameters, while the more 
sulfated HA20S10 chain presents an intermediate behavior characterized by disordered but 
more folded structures. Moreover, Fig. 1.5 B shows that the HA20S5 polymer has a vastly 
greater flexibility since it repeatedly changes its whole conformation bouncing between 
conformations quite similar to those of HA20S10 (i.e., d ~ 50 Å) and conformations vastly 
more extended (i.e., d ~ 70 Å) without reaching an equilibrium phase. 
Notably, Table 1.2 shows that the described differences between sulfated and non-
sulfated oligomers are maintained also when simulated in chloroform, which was chosen 
to simulate an apolar medium roughly comparable to the skin environment. Indeed, HA20 
assumes a contracted left-handed helix conformation also in chloroform, while HA20S5 
conserves an elongated and disordered geometry. The differences between simulation in 
water and chloroform are, on average, marginal even though one may note that the 
differences between sulfated and non-sulfated oligomers are a little reduced in chloroform 
and this can be ascribed to the increased solvent weight which slows down the solute 
movements due to molecular friction as well as to the inability of the solvent to stabilize 
strong interactions with the simulated oligomers.  
Altogether, the performed simulations allow some considerations to be done which can 
be summarized as follows: 
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 The non-sulfated chains assume quite ordered left-handed helices and this is in 
clear agreement with the experimental data. As a trend, the simulations suggest that 
conformational compactness increases with polymer length. 
 The sulfated chains lose the ordered helical motif and assume quite disordered 
structures, the less sulfated being more flexibly extended than the HA20S10 chain. In 
all simulated polymers conformational rigidity increases with the number of charged 
groups probably because the repulsion between them plays a dominant role with few 
charged groups, while an increased number of charged moieties tends to generate an 
ordered reticulum of ion-pairs which stabilize the polymer conformation [22]. 
 The observed conformational differences were found to be not markedly 
influenced by the polarity of the simulated media. At least, they are somewhat affected 
by solvent friction which however cannot alter the overall conformational profile. 
 
 
1.4 Conclusions 
 
Although the moisture content of stratum corneum and the aqueous composition of the 
epidermis permit a significant permeation also for hydrophilic compounds, the skin 
permeation of small organic molecules strongly decreases when increasing molecular 
size, polarity and the number of H-bonding groups [1; 23].  
The present study clearly evidences that the investigated biopolymers do not obey the 
aforementioned physicochemical rules. Indeed, the reported experimental results 
evidenced that hyaluronans have a great affinity for keratin and likely cross human 
stratum corneum and epidermis mainly through corneocytes rather than intercellular 
lipidic network. Moreover, the obtained results clearly indicate that sulfated polymers 
penetrate in a larger extent than the corresponding hyaluronic acids (Table 1.1), despite 
their vastly greater polarity.  
The molecular dynamics study can help to rationalize these data, shifting the focus on 
polymer flexibility and evidencing how the observed penetration behavior can be 
rationalized by the polymer’s conformational profile. In particular, the normalized values 
of radius of gyration were found to be in line with the extent of diffusion across the 
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stratum corneum and epidermis over 24 hours, the higher the values of radius of gyration, 
the higher the diffused amount.  
Such a trend can be explained considering that the penetration increases with the capacity 
to assume extended and flexible structures which can easily adapt themselves to the skin 
environment, which deeply changes due to the different composition of the viable 
epidermis, corneocytes and lipophilic network.  
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Abstract 
 
Low molecular weight heparins (LMWHs) are produced from heparin by different 
depolymerization methods that determine different molecular weights (Mw) and the 
formation of new structural features on the polysaccharide backbone; moreover, sodium 
or calcium can be used as counter-ions. This work aimed to elucidate the effect of these 
factors on the in vitro penetration of LMWHs through human epidermis. LMWHs were 
assayed determining the ability to inhibit the Factor Xa. The average Mw seemed to play 
a role in defining the extent of skin penetration of LMWHs. Indeed, Pearson correlation 
between the log MW and the amount permeated through the epidermis of sodium LMWHs 
resulted -0,758. Also the chemical features of LMWHs seemed to have an effect on the 
permeation process, with bemiparin and enoxaparin, obtained by β-elimination processes, 
which exhibited the best diffusion properties (Jbemiparin = 11.1 ± 0.3 and Jenoxaparin = 7.9 ± 
1.9 mIU/cm2h). In contrast, parnaparin, which maintained the chemical features of 
heparin, showed the lowest diffusion and the greatest affinity for the epidermis. Finally, 
the circular dichroism analyses performed on nadroparin revealed that the use of calcium 
as counter-ion reduced the chain mobility and consequently significantly decreased the 
LMWHs permeation through the epidermis.  
. 
 
 
 
 
 
 
 
 
 
 
 
 
The content of this chapter has been submitted for publication to an international peer-reviewed 
journal.  
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2.1 Introduction 
 
Low molecular weight heparins (LMWHs) are anticoagulant and antithrombotic drugs, 
mainly used in the prevention and treatment of deep vein thrombosis (DVT) after major 
surgical procedures.  
They have almost one third of the molecular mass of unfractionated heparin (UFH) and 
exhibit a lower affinity for plasma proteins thus providing more predictable effects, better 
pharmacokinetic parameters and safety profile (e.g. lower risk of bleeding and heparin-
induced thrombocytopenia) [1]. Therefore, they are currently administered to outpatients 
replacing in clinical practice the use of UFH [2]. 
LMWHs available on the market are obtained by four different depolymerization 
strategies of UFH, namely deaminative cleavage, chemical or enzymatic β-elimination 
and oxidative cleavage with radical agents. Depending on the specific reaction and the 
cleavage points along the UFH chain, LMWHs vary for average molecular weight (Mw) 
and molecular weight distribution, degree of sulfation, and peculiar terminal end residues, 
which are artifacts of the production process. As an example, LMWHs obtained by 
deaminative cleavage with nitrous acid present a 2,5-anhydro mannose residue at the 
reducing end, whereas β-elimination in alkaline conditions produces 4-enopyranose 
uronate residues at non reducing ends and N-sulfoglucosamine at the reducing end (Table 
2.1) [3; 4]. LMWHs obtained by different depolymerization methods are then dissimilar 
in structure, and exhibit distinct physical, chemical and biological properties [5].  
In the last decade, several efforts were made to propose non-invasive alternatives to 
subcutaneous route of administration [6]. The poor intestinal absorption together with the 
degradation of heparins both in liver and in gastrointestinal tract make the oral 
administration not feasible [7]. Transdermal delivery may represent a valid alternative, 
even if LMWHs diffusivity through the skin is limited by large Mw, hydrophilicity and 
negative charge [8]. These issues along with the possible strategies to enhance LMWHs 
permeation through the skin can be easily deduced by literature data [9]. However, since 
these strategies were mainly applied to a specific LMWH, a systematic evaluation of the 
impact of the main features of such polysaccharides on their permeation profile is still 
missing to the best of our knowledge. 
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With a view to getting an insight on the influence of the production method and the 
resulting structural features of LMWHs on permeability properties, the current work 
explored the in vitro passive diffusion through human epidermis of six commercially 
available LMWHs in comparison with UFH.  
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Table 2.1- Main features of tested LMWHs 
Depolymerization 
method 
LMWH  Substrate 
Average Mw 
(Da) 
Major non reducing end Major reducing end 
Deaminative 
cleavage 
(nitrous acid) 
Nadroparin UFH 4,300 2-O-sulfo-α-l-idopyranosuric acid 
6-O-sulfo-2,5-anhydro-d-
mannitol 
Dalteparin UFH 6,000 2-O-sulfo-α-l-idopyranosuric acid 
6-O-sulfo-2,5-anhydro-d-
mannitol 
Reviparin UFH 3,900 2-O-sulfo-α-l-idopyranosuric acid 
6-O-sulfo-2,5-anhydro-d-
mannitol 
β-Eliminative 
cleavage 
Enoxaparin Benzyl ester of UFH 4,500 2-O-sulfo-4-enopyranose uronate 
2-N,6-O-disulfo-d-
glucosamine 
Bemiparin UFH benzethonium salt 3,800 2-O-sulfo-4-enopyranose uronate 
2-N,6-O-disulfo-d-
glucosamine 
Radical-catalysed 
depolymerization 
Parnaparin UFH 5,000 2-O-sulfo-α-l-idopyranosuric acid 
2-N,6-O-disulfo-d-
glucosamine 
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2.2 Experimental section 
 
2.2.1 Materials 
 
Sodium enoxaparin (Clexane®, Sanofi Aventis), sodium parnaparin (Fluxum®, Alfa 
Wasswemann), calcium nadroparin (Fraxiparina®, GlaxoSmithKline), sodium dalteparin 
(Fragmin®, Pfizer), sodium reviparin (Clivarina®, Abbott) and sodium bemiparin (Ivor®, 
Sigma-tau). Sodium UFH (activity 195 IU/mg) was kindly donated by LDO S.p.A. 
(Milan, Italy). WHO 3rd International Standard for Low Molecular Weight Heparins 
(NIBSC code: 11/176) was kindly gifted by Italfarmaco S.p.A. (Cinisello Balsamo, Italy). 
Kit Coatest® Heparin was purchased by Chromogenix Instrumentation Laboratory S.p.A. 
(Milan, Italy). Ethylenediaminetetracetic acid disodium salt (EDTA) was purchased by 
Carlo Erba Reagenti (Milan, Italy). Trypsin-EDTA (0.05% trypsin, 0.02% EDTA) 
solution with phenol red was purchased by EuroClone S.p.A. (Pero, Italy). All other 
reagents were of analytical grade unless specified. 
 
2.2.2 In vitro human skin permeation studies 
 
In vitro permeation tests were performed by using Franz diffusion cells and human 
epidermis as membrane. The vertical cells used in the set of experiments have a wider 
column than the original Franz-type diffusion cell with a diffusion area of 0.636 cm2 and 
an average receptor volume of 3.0 mL. Abdominal human skin was obtained by healthy 
volunteers who underwent cosmetic surgery. Samples were prepared according to an 
internal standard protocol [10]. 
The integrity of tissue was preliminary assessed by measuring the electrical impedance 
of epidermis sheets (voltage: 250 mV, frequency: 100 Hz; Agilent 4263B LCR Meter, 
Microlease, Italy). Only samples with values above 40 kΩcm2 were considered suitable 
and used for the test.  
The human epidermis was mounted on lower half of the Franz cell and the upper and 
lower parts of the cell were sealed with Parafilm® and fastened together by means of a 
clamp. The receiver compartment was filled with a 0.05 mol/L Tris-EDTA buffer at pH 
Chapter 2 
44 
 
7.4 containing 100 µg/mL of sodium azide as preservative, and continuously stirred with 
a magnetic bar. Donor compartment was loaded with 500 µL of LMWH or UFH solution 
corresponding to a concentration of 2000 IU/mL. 
Particular care was taken to avoid the formation of air bubbles between the membrane 
and the receptor compartment. The system was kept at 37 ± 1 °C by means of a circulating 
water bath so that the epidermis surface temperature was at 32 ± 1 °C throughout the 
experiment.  
At predetermined times, 0.2 mL of receiving phase were withdrawn and replaced with 
fresh medium in order to maintain sink conditions. 
Only biologically active permeate was analyzed according to the procedure reported 
below. At least one control cell loaded with pure saline solution was included in each 
experiment in order to assess the interference of skin components in the biological assay. 
At the end of the in vitro permeation tests, the amount of active substance retained into 
the epidermis was also determined (R24). Briefly, tested solutions were withdrawn from 
the donor compartments and the permeation areas were circumscribed. SCE sheets were 
removed from the cells and cut within the permeation area to obtain sections of 0.2 cm2 
each. These were cleaned with a cotton swab and washed in water to remove any residual 
trace of LMWHs solution and let to dry.  
The extraction of LMWHs from the skin was carried out modifying the method proposed 
by Song [11]. Epidermis sections were weighted, immersed in 5 mL of 0.05 mol/L Tris-
EDTA buffer, vortexed for 2 min exacts and sonicated for 20 min. Then, samples were 
incubated at 37 ± 0.1 °C for 2 hours under agitation prior to be filtered with 0.45 µm 
acetate cellulose membrane and analyzed.  
The cumulative amount of drug permeated through the skin per unit area was calculated 
from the concentration of the permeant in the receiving medium and plotted as a function 
of time. The steady flux (J) was determined as the slope of the linear portion of the plot.  
 
2.2.3 UFH or LMWHs determination 
 
UFH or LMWHs biological activity was measured by using the Coatest® kit 
(Chromogenix, Instrumentation Laboratory S.p.A.) for the photometric determination of 
UFH. This relies on the ability of heparins-antitrombin III (AT) complex to react with an 
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excess of factor Xa (FXa). Unreacted FXa is hydrolyzed by a chromogenic substrate and 
read spectrophotometrically at 405 nm. The absorbance is inversely proportional to 
LMWHs concentration. The manufacturer protocol was slightly modified. Test and 
standard samples were prepared into the stock buffer solution and directly combined with 
AT without further dilutions. A volume of 100 µL test solution were incubated with AT 
in the 1:1 ratio for 3 min at 37 ± 1 °C. Subsequently 100 µL of FXa were added and, after 
vortexing, the mixture was re-incubated at 37 ± 1 °C for 30 s. 
The unreacted FXa was hydrolyzed by adding 200 µL of chromogenic substrate S-2222. 
After incubation for 3 min at 37±1 °C, the reaction was stopped adding 300 µL of 20% 
acetic acid. 
The assay was carried out in parallel for the blank solution. 
Calibration curves in the range 0.1-0.003 IU/mL were built up by using the international 
standard for LMWHs and sodium UFH. 
 
2.2.4 Circular dichroism (CD) 
 
CD spectra were recorded on a J-810 spectropolarimeter, using a quartz cuvette of 0.1 cm 
path length, between 190 and 260 nm at a scanning rate of 50 nm/min with 0.5 nm 
resolution. The analysis was carried out on 10 mg/mL samples in water at room 
temperature. To obtain a solution of sodium nadroparin, the commercial calcium 
nadroparin was treated with 1.4% w/v disodium EDTA. After overnight incubation, the 
salts were removed by ultrafiltration and the recovered sample was reconstituted to the 
original volume.  
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2.3 Results 
 
All molecules permeated the epidermis to a very low extent (Table 2.2). In the case of 
calcium nadroparin and UFH, the permeated amounts were quantifiable only at the end 
of experiments and, therefore, the fluxes were not calculated.  
With the exception of parnaparin, all sodium LMWHs showed a Q24 almost 10-fold higher 
than that of UFH, the precursor with the complete polysaccharide chain.  
Bemiparin, characterized by the lowest Mw, showed Q24 and J values higher than those 
found for all LMWHs tested (p<0.03), with the exception of enoxaparin, which shares the 
same chemical residues at the terminal ends (Table 2.1). In contrast, parnaparin, obtained 
by radical depolymerization, exhibited the lowest J among sodium LMWHs (p<0.006). 
Within the class of molecules obtained by deaminative cleavage, dalteparin permeated 
less than reviparin (p<0.05) in agreement with its higher Mw (Table 2.1). 
The pattern of calcium nadroparin appeared anomalous because this molecule permeated 
the epidermis to a very low extent in spite of the Mw (Mw = 4,300 Da) close to that of 
enoxaparin (Mw=4,500) and with respect to the compounds obtained by the same 
synthetic strategy, namely reviparin and dalteparin. This result was in agreement with that 
of Gooma and co-workers who reported the lack of passive permeation of calcium 
nadroparin both through animal and human cadaveric skin up to 48 hours [8]. To verify 
if this feature could be attributed to the influence of the counter-ion (i.e. calcium instead 
of sodium), the in vitro skin permeation of a solution of calcium nadroparin containing 
0.05% of disodium EDTA was assessed. The addition of the chelating agent improved 
the permeation of nadroparin, which became similar to that of reviparin, but did not affect 
the amount retained into the human epidermis at the end of the experiments, R24 (Table 
2.2).  
The R24 values were almost an order of magnitude higher than Q24, in all cases. 
Furthermore, the R24 of all LMWHs resulted 10-fold higher than the value determined for 
UFH. Finally, this parameter did not appear to be influenced both by the production 
process and type of counter-ion since any significant difference was determined among 
the LMWHs (One way ANOVA p=0.07, Table 2.2).  
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Table 2.2- Main permeation parameters of the tested compounds (mean value ± SE) 
Compound 
Q24 
(IU/cm2) 
R24 
(IU/cm2) 
J 
(IU/cm2 h x 10-3) 
Calcium nadroparin 0.001 ± 0.000 1.117 ± 0.197 - 
Sodium nadroparin* 0.157 ± 0.049 0.992 ± 0.058 5.3 ± 0.9 
Sodium dalteparin 0.115 ± 0.000 1.431 ± 0.203 6.2 ± 0.0 
Sodium Reviparin 0.147 ± 0.002 1.737 ± 0.172 7.1 ± 0.1 
Sodium Enoxaparin 0.179 ± 0.045 0.837 ± 0.221 7.9 ± 1.9 
Sodium Bemiparin 0.212 ± 0.020 1.300 ± 0.213 11.1 ± 0.3 
Sodium Parnaparin 0.008 ± 0.005 1.571 ± 0.550 0.1 ± 0.1 
UFH 0.001 ± 0.000 0.103 ± 0.029 - 
*Nadroparin calcium/0.05% Na2 EDTA solution 
 
2.4 Discussion 
 
The considered LMWHs globally permeated the epidermis to a low extent after 24 hours 
of application in agreement with the literature data [8; 11; 12; 13; 14; 15]. The lack of 
diffusion of these compounds through the skin can be justified considering the large 
molecular size and hydrophilicity and the repulsive forces between the negatively charges 
of lipids of stratum corneum and LMWHs [12]. However, some significant difference 
among the tested compounds was found.  
An overview of the obtained data evidenced that the most critical parameter affecting the 
permeation process through the human epidermis of LMWHs is the nature of the counter-
ion. As demonstrated in the case of nadroparin, the substitution of calcium with sodium 
determined an improvement of the Q24 of about two order of magnitude without affecting 
the R24 values. We attributed this behavior to a possible influence of the type of counter-
ion on the chain flexibility of the LMWHs. In order to confirm this hypothesis the circular 
dichroism (CD) spectra of the two compounds were recorded (Figure 2.1). The 
substitution of Ca2+ ions with Na+ ions determined a significant increase of the intensity 
and a slight red shift (211.5 nm vs 210 nm) of the negative band centered at about 210 
nm, relative to n→π* transitions of amide and carboxyl groups across the β 1,4-linkage. 
These differences in the CD spectra were attributed to the formation of an intramolecular 
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chelate in which calcium binds two adjacent carboxyl groups within the same chain [16]. 
The formation of such complex limits the rotation along the glycosidic linkage lowering 
the flexibility of the molecule [17] and therefore its ability to diffuse through the 
epidermis. This result is also in agreement with those obtained using hyaluronan and 
sulfates thereof, which revealed a relationship between the passive permeation through 
the epidermis of glycosaminoglycans and their ability to assume a flexible structure 
during the diffusion across the skin environment [18]. 
 
 
 
Figure 2.1 – CD spectra of nadroparin: effect of the counter-ion  
 
 
 
Among the variables considered in the study, also Mw resulted to play an important role 
in determining the trend of penetration of such polysaccharides. Indeed, an acceptable 
Pearson correlation between the Log Mw and Q24 values determined for sodium LMWHs 
was found (R= -0.753). However, the Mw did not completely explain the diffusion pattern 
of LMWHs. As an example, the J value of parnaparin, having a Mw of 5,000, was about 
an order of magnitude lower than the J determined for dalteparin (Mw 6,000). Moreover 
the Q24 values found for parnaparin and UFH did not result to be statistically different 
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(p>0.05), in spite of the significant larger molecular weight distribution of UFH. Such 
evidences suggested that the structural features resulting from the different 
depolymerization processes also exert a fundamental role in determining the extent of 
permeation of these macromolecules through human epidermis. Indeed, the similar 
penetration pattern of parnaparin and UFH can be justified by the fact that the oxidative 
breakage of UFH chain does not involve substantial modifications of the oligosaccharide 
sequence and, consequently, parnaparin shares almost the same chemical residues of the 
precursor. Moreover, the oxidative strategy leads to molecules with slightly higher degree 
of sulfation [4] and, hence, higher polarity, and this negatively impacted on the diffusion 
through human epidermis.  
In contrast, β-elimination method causing the formation of unique chemical features, i.e. 
unsaturated uronic acid residues at the non-reducing end (Table 2.1), seemed to enhance 
the permeation of LMWHs with respect to the other synthetic strategies (Table 2.2). 
Thus, the highest flux determined for bemiparin can be justified considering both the 
lowest Mw and the 2-O-sulfo-4-enopyranose uronate residues at the non-reducing ends. 
The amount of LMWHs retained into the human epidermis at the end of the experiments 
was, in all cases, almost an order of magnitude higher than Q24, underling the worst ability 
of these molecules to diffuse through the human epidermis. Indeed, it was already 
demonstrated the interaction of UFH/LMWHs with skin cells, mainly keratinocytes, due 
to their chemical structure and, more specifically, N-acetylglucosamine-6-sulfate moiety 
[8; 19], consistently with the topical application of LMWHs. Indeed it was suggested that 
the autocrine activation of epidermal growth factor receptor (EGFR) mediated by 
interaction of heparins with keratinocytes, may be exploited in cutaneous wound healing 
and some dermatologic disorders characterized by hyperplasia, such as psoriasis [20; 21; 
22]. In this latter case, the design of a cutaneous dosage form should involve a drug which 
couples the affinity for the epidermal layers with the inability to permeate the skin. In this 
light, we calculated the R24/Q24 ratio for each LMWH as an appropriate descriptor, 
assuming that the greater the ratio, the greater the affinity for the epidermis layers. Figure 
2.2 evidenced that, among the sodium LMWHs, parnaparin showed the greatest affinity 
for the epidermis. As stated above, parnaparin is obtained by a radical method which 
causes such a natural break of the UFH chain and, therefore, the residues and the 
oligosaccharide sequence of UFH, included the moieties responsible for the binding to 
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keratinocytes, are well-conserved. Finally, it should be underlined that the use of bivalent 
cations favors the retention into the epidermis as demonstrated in the case of calcium 
nadroparin.  
 
 
 
 
       Figure 2.2- R24/Q24 ratio of LMWHs and UFH. Greater the value greater the affinity of the 
       tested compound for the human epidermis.  
 
 
 
 
2.5 Conclusions 
 
The influence of the main chemical features of LMWHs (Mw, structural residues and 
nature of counter-ion) on their ability to diffuse through human epidermis was elucidated. 
Altogether, the experimental data proved that the chain flexibility is the most evident 
parameter which influences the penetration pattern of these macromolecules. Indeed, the 
Ca2+, limiting the rotation along the glycosidic leakage, significantly decreased the skin 
diffusion of nadroparin with respect to the sodium LMWHs. 
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As for the other variables in study, Mw, whose relevance in ruling the permeation of small 
molecules through human skin is well-established, was found to drive to a certain extent 
also the skin permeability of this class of polysaccharides. 
However, in the case of such complex macromolecules, it couldn’t completely explain 
the observed trend of permeation. In fact, the depolymerization method which confers to 
each LMWH unique properties in terms of residues at the terminal ends, oligosaccharide 
sequence and distribution of sulfate regions, resulted to play a fundamental role in 
defining the penetration pattern of LMWHs. In particular, bemiparin and enoxaparin, 
obtained by β-elimination, showed the best permeability properties (the highest 
permeation and the lowest R24/Q24 ratios) and therefore they appeared as the most suitable 
candidates for a regional or systemic delivery. Nevertheless, a powerful enhancement 
strategy should be considered to improve the poor passive flux through human skin to an 
extent which is compatible with a therapeutic effect. Finally, it should be also underlined 
that LMWHs with high R24/Q24 ratios such as nadroparin calcium and parnaparin, could 
be further investigated for cutaneous applications. 
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3.1 Introduction 
 
Skin penetration enhancers represent a long-standing approach for improving transdermal 
delivery of drugs. They are usually small molecules able to perturb the organization of 
stratum corneum, which represents the main barrier for the penetration of xenobiotics.  
In recent years, peptides able to diffuse through the epidermis layers have been also tested 
to improve the transcutaneous delivery of drugs [1]. As an example, polyarginine has 
been shown to ferry molecules across the stratum corneum and into the viable epidermis 
and dermis [2]. Magainin, a naturally occurring pore-forming peptide, was found to 
increase skin permeability by direct interaction with and disruption of stratum corneum 
lipids [3; 4].  
Among the possible approaches to screen new skin penetrating peptides, the use of phage 
display peptide libraries is gaining a growing interest [5; 6; 7].  
Phage display is a powerful technology for ligand identification, since large libraries 
expressing peptides or proteins can be screened for target affinity [8].  
The first application of phage display aimed to find a peptide which could specifically 
improve the skin penetration of administered molecules was performed by Chen and 
coworkers, who identified a peptide that increased the transdermal absorption of insulin 
in diabetic rats through hair follicles [5]. Using the same approach, Kumar et al. selected 
a 6-mer peptide which improved the penetration of 5-fluorouracil through porcine and 
mouse skin [6]. However, the most exhaustive study in this field was carried out by Hsu 
and Mitragotri. Indeed, the identification of the SPACE peptide provided the first 
evidence that skin penetrating peptides are able to penetrate the human skin [7]. 
Furthermore SPACE resulted to be effective in enhancing the skin penetration of nucleic 
acids and polysaccharides by direct conjugation to the cargo [7] or grafting on the surface 
of nanocarriers [9]. 
Altogether, these data revealed that the use of skin penentrating peptides can improve the 
challenging transdermal delivery of large hydrophilic molecules, overcoming the limits 
of the conventional chemical enhancers [10].  
Heparin (UFH) has been the anticoagulant and antithrombotic drug of choice for several 
decades even if nowadays its use is restricted to the hospital where it is possible a careful 
clinical monitoring of the patients. Indeed, the intravenous administration of UFH can be 
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associated with serious complications such as bleeding risk, thrombocytopenia, effect on 
bone metabolism, along with pain and poor patient compliance [11]. The delivery of the 
drug by an alternative, non invasive route of administration may alter the 
pharmacokinetic/pharmacodynamic profiles and, therefore, potentially minimize the side 
effects, increasing at the same time patient compliance [12]. In particular, topical 
application appears as the most attractive alternative to UFH injection since it allows a 
substained release of the drug with possibility to have either a systemic (transdermal) or 
local effect [1; 12]. In fact, the cutaneous administration of UFH has also a clinical 
relevance in the prevention and treatment of the symptoms associated to peripheral 
vascular disorders, requiring however the application of huge doses of drug to reach the 
desired antithrombotic effect [13]. 
The skin penetration of UFH is very poor due to its unfavorable physico-chemical 
features, namely high Mw, hydrophilicity and ionization [14] and, therefore, a suitable 
method to improve the UFH diffusion through the skin is desired. 
This study aimed to identify a new skin penetrating peptide able to enhance the 
penetration of UFH through human epidermis. The selection was performed by screening 
a random 7-mer phage display peptide library.  
Furthermore, to clarify the enhancement mechanism of the peptide, its effect on the 
permeation of small molecules was also studies. Lidocaine and propranolol-HCl were 
selected as model drugs since they are used for local anesthesia and haemangiomas, 
respectively [15; 16]. 
 
 
3.2 Materials and Methods 
 
3.2.1 Materials 
 
The Ph.D.-7 Phage Display Peptide Library and escherichia coli K12 strain ER2738 were 
obtained from New England Biolabs. Luria Broth, agar, NaCl, Blue/white select, 
polyethylene glycol−8000 (PEG8000), tris-HCl, sodium azide were purchased by Sigma-
Aldrich (Italy). Tetracycline was purchased by Fluka Analytical. N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and N-
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Hydroxysulfosuccinimide sodium salt (sulfo-NHS) were purchased by Sigma Aldrich 
(Italy). Propranolol-HCl and lidocaine were purchased by Sigma-Aldrich (St. Louis, 
MO). Sodium UFH (activity 195 IU/mg) was kindly provided by LDO S.p.A. (Milan, 
Italy). Kit Coatest® Heparin was purchased by Chromogenix Instrumentation Laboratory 
S.p.A. (Milan, Italy). 
 
3.2.2 Preparation of human epidermis samples 
 
The epidermis used in the permeation studies was obtained from the abdominal skin of 
three donors, who underwent cosmetic surgery (30-50 year old, Eurasian female). Skin 
samples were prepared following an internal standard procedure [17]. The full-thickness 
skin was sealed in evacuated plastic bags and frozen at -20 °C within 24 h after removal.  
Prior to the experiments, the skin was thawed at room temperature and the excess of fat 
was carefully removed. The skin sections were cut into squares of about 2.5 cm2 and, after 
immersing the skin in water at 60 °C for 1 min, the epidermis was gently separated from 
the remaining tissue with forceps and carefully inspected by light microscopy for any 
defects. The integrity of the tissue was assessed by measuring the electrical impedance of 
the epidermis sheets (voltage: 250 mV, frequency: 100 Hz; Agilent 4263B LCR Meter, 
Microlease, Italy). The human epidermis was hydrated and sandwiched between the 
donor and the receptor compartments (both filled with physiologic solution), with the 
stratum corneum facing the donor compartment. The receptor phase was kept at 37 ± 1 °C 
with continuous stirring (1800 rpm) for 30 min and then the impedance was determined. 
 
3.2.3 Phage Display Library Screening 
 
Physiologic solution was used in the receptor compartment and sodium azide (0.1%) was 
added as a preservative. The epidermis was equilibrated for 1 h before the experiment. 
Phage library (2 × 1013 pfu, 50 μL) in 0.45 mL of TBS was placed in the donor 
compartment. After 24 h, the receiver medium was withdrawn and 1 mL was added to 20 
mL of a 1∶100 diluted overnight culture of Escherichia coli ER2738 and grown for 4.5 h 
to amplify the phages. Then, the phages were purified by PEG∕NaCl precipitation and 
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resuspended in TBS. 0.5 mL amplified phages suspension were then used in the second 
round of screening. The number of phages placed in the donor compartment, 2 × 1013 pfu, 
was held constant for both rounds of screening. After the second round of selection, 
phages that permeated the human epidermis consistently were separated on an agar plate. 
A 10-μL aliquot of the receiver solution was added to 10 μL of Escherichia coli strain 
ER2738 and plated on IPTG/Xgal plates. 20 plaques were randomly selected and the 
DNA from each individual plaque, representing a single type of phage, was extracted and 
sent for DNA sequencing (BMR Genomics, I). 
 
3.2.4 Peptide synthesis and characterization 
 
The peptide selected by phage display was synthetized by microwave assisted solid phase 
peptide synthesis using the Fmoc-Chemistry (Liberty Microwave Peptide Synthesizer, 
CEM Corporation) [18]. The peptide was C-terminally amidated and N-terminally 
acetylated using Rink amide resin with a loading of 0.5 mmol g-1 and on a 0.1 mM scale. 
Single couplings were performed with Fmoc-amino acid (5 eq) activated in situ with 
HBTU (5 eq), HOBt (5 eq) dissolved in DMF, and DIPEA 1M in NMP (10 eq); each 
coupling was achieved by using MW irradiation (5 min, 75 °C, 20W). Fmoc cleavage 
was accomplished by treating the peptidyl-resin with 20% piperidine in DMF (3 min,  
75 °C, 40 W). N-acetylation was performed manually using acetic anhydride (10 equiv.) 
and DIPEA (10 equiv.) in DCM for 30 min at room temperature. The peptide was 
manually cleaved from the resin with a mixture of TFA/water/TIS (90:5:5 v/v) for 6 h at 
room temperature. The crude peptide was precipitated from ice-cold diethyl ether and 
recovered by centrifugation at 4°C for 5 minutes (4500 rpm). The crude peptide was 
dissolved in DMSO and diluted in ACN/water (50:50 v/v) solution. The purification was 
performed by preparative RP-HPLC (Jasco BS-997-01 equipment) using a DENALI C-
18 column from GRACE VYDAC (10µm, 250 x  22 mm) and a combination of two 
mobile phases: A = 95% Water, 5 % ACN, 0.1 % TFA; B = 95% ACN, 5% Water, 0.1% 
TFA. 2 mL of peptide solution were injected at a flow rate of 20 mL/min. The gradient 
was: 95% A for 5 min, then 95-30% A over 20 min. UV detection was made at 220 nm. 
The purified peptide was freeze-dried and stored at 0°C.  
Chapter 3 
60 
 
The conformational profile of the synthetic peptide was investigated by circular 
dichroism (CD). 
Peptide stock solution was prepared in HPLC-quality water (500 µM, 1.5 mL). Spectra 
were  recorded on a J-810 spectropolarimeter, using a quartz cuvette of 0.01 cm path 
length (Hellma Suprasil), from 195 to 250 nm with a 0.1 nm step and 1 s collection time 
per step, taking three average. The spectrum of the solvent was subtracted to eliminate 
interference from cell, solvent, and optical equipment. The CD spectra were plotted as 
mean residue ellipticity θ (degree x cm2 x dmol-1) versus wavelength λ (nm). Noise-
reduction was obtained using a Fourier-transform filter program from Jasco. 
 
3.2.5 Fourier Transform Infrared (FTIR) Spectroscopy 
 
ATR-FTIR spectra were recorded between 4,000 and 650 cm−1 using a Bruker Alpha-P 
spectrometer (128 scans; 4 cm−1 resolution), equipped with an attenuated total reflection 
diamond crystal accessory. The spectrometer was linked to a PC equipped with Bruker 
OPUS software to allow the automated collection of IR spectra.  
Human epidermis was soaked in demineralized water or in a solution of the peptide (0.25 
or 0.5 mg/mL) in water for 1 h, then allowed to dry at room temperature for 15 min. The 
IR spectrum was recorded on epidermis sheets incubated with and without peptide, thus 
each epidermis sample acted as its own control at each time.  
All measurements were performed at room temperature, 25 ± 2°C. The spectra were 
smoothed and baseline-corrected. The skin lipids absorbance peaks at 2920 cm−1 and 
2850 cm−1 were monitored and variations in the ratio of peak height or area after peptide 
treatment were determined in comparison to the control. 
Fourier self-deconvolution (FSD) of the overlapping amide I band components 
(1705−1578 cm−1) was performed by using OPUS 7.5 software (Bruker). The amide I 
bands were resolved by the second-order derivative with respect to the wavelength. 
Deconvolution was performed using Gaussian line shape.  
Since the ATR technique is very sensitive to the contact state during the measurements 
and the overall intensity of the spectra varied, it was necessary to normalize the spectra. 
The most intense protein band was the amide I band at 1650 cm-1 and therefore it was 
chosen as internal standard. 
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3.2.6 In Vitro Skin Permeation Studies  
 
In vitro skin permeation studies were performed using human epidermis in a Franz 
diffusion cell. 
The tested donor solutions were: 0.5 mL peptide (0.5 or 5.0 mg/mL) or 0.5 mL 
propranolol (0.2 % w/v) or 0.5 mL lidocaine (0.3 % w/v) or 0.3 mL UFH (6.7 mg/mL) 
saline solutions containing 0.1% sodium azide. All the experiments were repeated 
preparing the same solutions containing 0.5 mg/mL peptide. Finally, 0.3 mL UFH-peptide 
conjugate (6.7 mg/mL) was also tested. 
The receiver solution (3.0 mL, exactly measured) was saline solution in the case of the 
peptide and small molecules and tris buffer 0.05 mol/L, pH 7.4 for UFH and UFH-peptide 
conjugate. 
The system was kept at 37 ± 1 °C by means of a circulating water bath so that the 
epidermis surface temperature was at 32 ± 1 °C throughout the experiment and the 
receiver medium was continuously maintained under stirring with a magnetic bar.  
At predetermined time intervals, samples (0.2 mL) were withdrawn from the receptor 
chamber and an equivalent volume of fresh medium was added to maintain the sink 
condition. The tests were always carried out using in parallel pure saline solution in the 
donor phase as control.  
The steady-state flux (Jss, μg/cm2/h) was calculated from the slope of the linear plot of 
the cumulative amount of the drug permeated per unit area (Q, μg/cm2) as a function of 
time (h). The lag time (h) was determined from the x-intercept of the slope at steady-state. 
The enhancement factor (E.F.) was calculated as the ratio of the fluxes at the steady state. 
 
3.2.7 Drug assays 
 
The amounts of propranolol and lidocaine that permeated through human skin were 
assayed by HPLC, using an Agilent 1100 HPLC system (1100 autosampler, 1100 
quaternary pump with degasser, 1100 thermostated column compartment, and 1100 diode 
array detector) (Agilent, Palo Alto, CA). 
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Lidocaine determination - The analyses were performed in the following experimental 
conditions: column: 5 µm C-8, 150 mm x 4.6 mm (Supelco, USA); mobile phase: 
acetonitrile/water (adjusted to pH 2.5 by 85% ortophosphoric acid) (50/50 v/v); flow rate: 
1 ml/min; UV detector: 224 nm; injection volume: 20 µl; temperature: 20°C. The 
retention time was about 5 min. A calibration curve from 0.2 to 50 µg/ml was calculated 
on the basis of peak area measurements. It was generated with a correlation coefficient of 
0.99990. 
 
Propranolol determination - A reverse-phase column was used as the stationary phase 
(Bondclone C18, 10 µm, 3.9 x 300 mm, Phenomenex, USA) and a combination of 
acetonitrile with 0.2% phosphoric acid at the ratio of 40 to 60 at 25 °C was used as the 
mobile phase. The flow rate was set at 1.2 mL/min. The injection volume was 20 μL. The 
retention times of propranolol was 8 min. The drug concentration was determined from a 
standard calibration curve in the range of 0.2-20 μg/mL (correlation coefficient: 0.99996). 
 
UFH determination- UFH concentration was determined by measuring the anti FXa 
(aXa) activity using the Coatest® kit (Chromogenix, Instrumentation Laboratory S.p.A.). 
The method relies on the ability of UFH-antitrombin III (AT) complex to react with an 
excess of factor Xa (FXa). Unreacted FXa is hydrolyzed by a chromogenic substrate and 
read spectrophotometrically at 405 nm. The absorbance is inversely proportional to UFH 
concentration. The drug (UFH and UFH-peptide conjugate) concentration was estimated 
on the basis of calibration curves built in the range  0.03-0.5 µg/mL and 0.15-4.8 µg/mL, 
respectively. 
 
3.2.8 Synthesis of UFH-peptide conjugate  
 
The conjugation of UFH to the identified peptide was carried out according to 
Freudenberg et al. [19] with slight modifications. UFH (average MW 15,000 Da) and a 
mixture of EDC and sulfo-NHS (2:1 w/w) were dissolved in MilliQ-water on ice. A 5-
fold molar excess of activating agent with respect to UFH carboxylic acid (-COOH) 
groups was used. In parallel, the peptide was dissolved in MilliQ-water (UFH:peptide  1:1 
molar ratio) and kept on ice until its use. After vigorous mixing, the UFH and EDC/sulfo-
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NHS solution was incubated in ice (approx. 2–4 °C) for 15 min to activate the UFH-
COOH. Subsequently the peptide solution was added to the activated UFH. After 
vortexing and incubation for 10 min at 4 °C, the reaction mixture was maintained at room 
temperature under continuous stirring for 4-5 h. Afterwards, the reaction product was 
purified by ultrafiltration (membrane filters Microcon/Amicon, cut-off 3KDa) and the 
recovered conjugate was freeze-dried.  
 
 
3.3 Results  
 
3.3.1 Identification of Skin Penetrating Peptide 
 
After the two rounds of screening by in vitro phage display, the 7-mer peptide that 
consistently diffuses through the human epidermis resulted to be DRTTLTN. Indeed, the 
DNA sequencing revealed that 66% phages expressed such peptide on their surface.  
The identified sequence (skin penetration enhancer heptapeptide, SPEH) was thus 
chemically synthesized by microwave assisted solid phase peptide synthesis (MW-
SPPPS) and acetylated at the N-terminus using protocols previously optimized [18]. The 
conformational behaviour of SPEH was studied using circular dichroism (CD). The CD 
spectrum, shown in Figure 3.1, is characterized by the presence of a minimum at 198 nm 
and a negative shoulder around 220 nm, indicating that the peptide in these conditions did 
not possess a preferred conformation, but that different secondary structures (i .e. 310 helix 
and β) were present. The presence of a β structure was outlined also by ATR-FTIR 
analysis: in the amide I region of the spectrum a corresponding peak at 1635 cm-1 was 
observed. (Figure 3.2 b) A shoulder around 1663 cm-1, indicating a 310 helix contribution 
was also detected. 
 
 
Chapter 3 
64 
 
 
Figura 3.1 – CD Spectra of SPEH 
 
 
 
 
 
Figure 3.2- ATR-FTIR spectra of a) UFH, b) SPEH and c) UFH-SPEH conjugate  
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As depicted in Figure 3.3, the SPEH was able to penetrate into the skin in a significant 
amount even when removed from the phage. Indeed, the 40% of SPEH loaded in the 
donor compartment of the Franz cell permeated through the epidermis within 30 min, 
independently of its concentration. Moreover, in both the experiments, the system reached 
the equilibrium within six hours. 
 
 
 
 
       Figure 3.3- Permeation profile of SPEH  
 
 
 
A deeper insight on the diffusion through the epidermis and the effects on the organization 
of the major constituents of the stratum corneum was obtained by the analyses of the 
ATR-FTIR spectra. To assess the possible effect on molecular conformation of stratum 
corneum components, the spectrum of human epidermis of each donor exposed to water 
for 1 h was selected as reference (Figure 3.4 b).  
The assignments and peak position of the diagnostic bands in the spectra were attributed 
with reference to the literature [20].  
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Alteration of the spatial organization of lipidic lamellae of the stratum corneum due to 
the penetration of a compound can be evidenced by analyzing CHx stretching regions at 
about 2950-2850 cm-1. In particular, the change of conformation of the ceramides are 
detectable by shift of such bands to higher wavenumbers while the increase of the area 
and/or height of CH2 stretching (ν -CH2) peaks is associated to a fluidization effect. 
The incubation of the epidermis with SPEH did not determine any significant shift of the 
CH2 asymmetric (as-CH2) and symmetric (s-CH2) wavenumbers. However, the height of 
both these bands increased in the epidermis samples exposed to a 0.5 mg/mL SPEH 
concentration (Table 3.1). At lower level (0.25 mg/mL), the SPEH did not seem 
completely effective in determining the fluidization of the lipidic network, since the 
increase of the height of the s-CH2 band occurred only for one donor (Table 3.1). 
 
 
 
Table 3.1 – Peak areas of methylene bands arising from the lipids in the SC bilayers 
and changes in their intensity calculated as ratio between treated and untreated samples 
deriving from five different donors. 
Donor 
DRTTLTN 
(mg/mL) 
Epidermis 
sample 
νas(CH2) 
(height) 
Ratio 
νs(CH2) 
(height) 
Ratio 
a 0.5 
Untreated 0.65 
1.43 
0.335 
1.39 
Treated 0.93 0.464 
b 0.5 
Untreated 0.736 
1.53 
0.379 
1.66 
Treated 1.124 0.629 
c 0.5 
Untreated 0.033 
1.12 
0.017 
1.12 
Treated 0.037 0.019 
d 0.25 
Untreated 0.242 
1.36 
0.117 
1.552 
Treated 0.330 0.182 
e 0.25 
Untreated 0.380 
1.02 
0.225 
0.843 
Treated 0.388 0.190 
 
 
 
The other interesting band of the stratum corneum is the peak assigned to the C=O 
stretching of  the amide (Amide I) at about 1640 cm-1, which is the result of the contributes 
of the keratin conformation and presence of ceramides.  
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Figure 3.5 reports the Gaussian curve fitting of untreated epidermis samples. The bands 
were assigned, according to our previous work, as follows: 
1635 cm-1: intramolecular β-sheet (B);  
1694 cm-1 and bands in the 1627 cm-1 region: intermolecular β-sheets (B);  
1668 and 1689 cm-1 region: turn structure (T);  
1652 cm-1: random coil conformation (R);  
1660 cm-1: α-helices (A);  
1619 cm-1: ceramides contribute (C); 
1612 cm-1: keratin lateral chains vibrations (L). 
Furthermore, the band at about 1645 cm-1 was attributed to the H-O-H bending vibration 
(H) of epidermal moisture content.  
 
 
 
Figure 3.5- Absorbance spectra in the amide I region, deducted after Fourier transform self-
deconvolution of human epidermis incubated in physiologic solution for 1 hour. The black and 
purple curves represent the original and the fitted spectra, respectively. The attributions of each 
deconvoluted band are marked as R (random coil), B (β-sheets), A (α-helix), T (turns), L 
(lateral chains) and W (water). 
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The relative abundance (% area) of the deconvoluted bands suggested a possible 
interaction between SPEH and keratin because the percentages of the secondary 
structures of keratin changed in the treated samples (Table 3.2). In particular, the total 
areas attributed to random coils and -turns increased indicating that the keratin assumed 
a less ordered structure. The unfolding of the keratins due to the interaction with the SPEH 
was also confirmed by the reduction of the α-helix and -sheet conformations, suggesting 
that SPEH has the potentialities to enhance the transdermal permeation of 
macromolecules by loosening the keratin structure and increasing the degree of freedom 
for carbon movement [21]. 
 
 
 
Table 3.2 - Contribution from secondary structures of the deconvoluted amide I band in 
the ATR-FTIR spectra of human epidermis (stratum corneum side) treated with 
DRTTLTN compared with the untreated sample. 
Attribution Epidermis sample Area (%) P value 
L 
Untreated 7.37±2.42 
0.17 
Treated 5.16±1.32 
C 
Untreated 5.64±1.52 
0.43 
Treated 4.54±1.82 
B 
Untreated 21.92±6.61 
0.48 
Treated 18.89±3.92 
W 
Untreated 18.96±2.40 
0.95 
Treated 18.80±4.67 
R 
Untreated 3.90±4.09 
0.045* 
Treated 13.89±5.43 
A 
Untreated 22.37±0.57 
0.019* 
Treated 15.85±3.21 
T 
Untreated 19.83±2.39 
0.04* 
Treated 23.94±1.61 
* P<0.05 by Fisher test 
 
 
 
In summary, it could be hypothesized that the SPEH can enhance the permeation of drugs 
by two different mechanisms: the fluidization of the lipidic network and the decrease of 
the ordered structure of keratin filaments. 
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3.3.2 Enhancement effect of SPEH 
 
In order to demonstrate the skin penetration enhancement effect of SPEH on small 
molecules, the in vitro permeation through human epidermis of lidocaine and propranolol 
in presence of 0.5 mg/mL SPEH was determined (Figure 3.6). 
The addition of SPEH increased the fluxes of lidocaine and propranolol of 2.6 and 3.8 
fold, respectively. Moreover, the lag time determined for propranolol decreased from 
about 3 h to about 1 h. 
 
 
 
 
Figure 3.6 - Permeation profiles of lidocaine and propranolol-HCl (sole and in co-administration 
with SPEH) 
 
 
 
On the contrary, the co-administration of SPEH with UFH did not lead to an increase of 
permeation or retention of the polysaccharide (data not shown). The lack of enhancement 
can be ascribed to the affinity of UFH for keratin, as revealed by ATR-FTIR spectra of 
human epidermis. Indeed, after exposure of the epidermis to UFH for 1 h a significant 
depression of the bands at 1742 cm-1 and 1160 cm-1 attributed to the C=O stretching of 
ester groups was observed (Figure 3.4). The reduction of such bands, already described 
by Lanke et al. [22], suggested the formation of hydrogen bonds between UFH sulfones 
and hydroxyl moieties and some stratum corneum component [23]. This evidence can 
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justify the lack of improvement of UFH diffusion after the perturbation of the stratum 
corneum structures caused by SPEH, when the peptide and the cargo were co-
administered.   
 
 
 
 
Figure 3.4- ATR-FTIR spectra of a) UFH, b) stratum corneum, and c) stratum corneum 
exposed to UFH for 1 h 
 
 
 
To overcome the resistance related to the affinity of UFH for the stratum corneum, the 
cargo was conjugated with SPEH by amide bond formation. The biological activity of the 
UFH-SPEH conjugate was determined after synthesis in comparison to the native UFH. 
The adopted procedure led to a very significant reduction of the UFH aXa activity, namely 
about 5-fold (195 UI/mg for UFH vs 36 UI/mg for the conjugate). This reduction was 
attributed to an alteration of the spatial organization of the UFH due to the presence of 
the SPEH on the chain and/or to the substitution of the free carboxyl mojeties with 
succinimide esters formed with NHS during the attivation process. As a matter fact, the 
conjugation with the peptide was evidenced by ATR-FTIR spectroscopy since the amide 
I and amide II of the peptide shifted from 1635 cm-1 and 1536 cm-1 to 1643 cm-1 and 1558 
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cm-1, respectively (Figure 3.2). Furthermore the shoulder at 1663 cm-1 completely 
disappeared, indicating a stabilization of the β conformation of the peptide when linked 
to UFH. The presence of unreacted ester intermediates was also confirmed by ATR-FTIR 
analysis. A shoulder at about 1730 cm-1, tipical of ester function, was thus detected.  
The fluxes determined for the conjugate and free UFH resulted 1.36 µg/cm2/h and 0.04 
µg/cm2/h respectively, showing an enhancement factor equal to 34. However, considering 
the significant reduction of the anticoagulant activity of the conjugate, the true 
enhancement factor resulted to be about 7. 
 
 
3.4 Discussion 
 
The peptide identified in this study, SPEH, seems to interact strongly with both lipids and 
keratin. As it is well known, the stratum corneum is a lamellar structure consisting of 
approximately 10-15 layers of flattened, α-keratin-containing cells. Within the cells the 
α-keratin filaments, imbedded in an amorphous matrix of lipids and non fibrous proteins, 
are arranged roughly parallel to the plane of the membrane. Thus, the diffusion through 
stratum corneum can follow two different micropathways. The intercellular route is a 
continuous way through intercellular lipid domains. The diffusion by the transcellular 
pathway involves the permeation of the corneocytes and, in this case, the permeant has to 
cross the keratin and then the intercellular lipids [24].  
SPEH, penetrating into the intercellular region of stratum corneum, increases the fluidity 
of the lipid components and consequently the diffusion of drugs through the intercellular 
route. Secondly, as supported by ATR-FTIR data, the penetration of SPEH in the 
corneocites, causing the uncoiling and the extension of keratin filaments, can increase the 
diffusion of molecules through the transcellular route.  
The combination of these two mechanisms can justify the increase of the skin penetration 
of the two tested small molecules, namely lidocaine and propranolol. 
In the case of UFH, it is reasonable to think that the large hydrodynamic volume of the 
molecule prevents the penetration through the intercellular route. On the other hand, the 
transcellular penetration of sole UFH is precluded by its high affinity for corneocytes, 
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which causes the retention of the polysaccharide into the membrane, as suggested by other 
authors [25] and supported by the IR spectra of the epidermis exposed to UFH.  
In contrast, the chemical conjugation of the cargo to SPEH may partially reduce the 
interaction between UFH and stratum corneum due to the steric hindrance of the peptide 
grafted on the UFH backbone, thus providing the driving force for the permeation. Indeed, 
the depression of the C=O stretching at 1742 cm-1 noticead after the exposure of the 
human epidermis to UFH (Figure 3.4) was not observed when the membrane was treated 
with the conjugate (data not shown). Thus, the chemical conjugation of the cargo resulted 
to be essential to improve the skin delivery of such macromolecule which is driven by the 
diffusion of SPEH.  
The enhancement factor (E.F.) due to the conjugation of UFH with SPEH resulted greater 
than that described for other traditional skin penetration enhancers. Indeed, the 
pretreatment of the skin with Azone® (E.F.= 3.4) [26] resulted to be an order of magnitude 
lower than that found in our set of experiments (E.F.=34) and the use of an 
ethanol/limonene 99/1 blend determined an E.F. of 18 [27]. It should be mentioned that 
Azone® is not used in commercial drug products due to its skin irritancy and toxicity at 
certain doses, and the percentage of limonene to be included in topical products is limited 
by regulatory authorities. 
Aiming to improve the skin penetration of UFH, different physical methods were also 
exploited [28]. Prausnitz and coworkers demonstrated a significant increase of UFH flux 
after skin electroporation which was accompanied however by a strong reduction of the 
activity of the transported molecule (one eight of the applied compound) [14]. Similarly, 
the application of low-frequency ultrasounds seemed to improve consistently the in vitro 
permeation of radiolabeled UFH (flux 21-fold higher than control) [29]. Nevertheless, 
also in that case, the biological active samples assayed in the receiver compartement 
accounted for only 25-40% of all UFH permeated. Using iontophoresis, UFH flux was 
increased of about 10 fold [30] but the study of the different fraction pools 
(unfractionated, high-, and low molecular weight heparins) revealed that this technique 
had a limited effect on the diffusion of high molecular weight polysaccharides, suggesting 
the application of this system for the skin delivery of LMWHs [31]. Moreover, the 
application of pulsed current iontophoresis caused a significant decrease in aXa activity 
(almost 33%) [31].  
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A successful enhancement strategy should create the driving force for the transdermal 
delivery in a safe manner. In this regard, the perturbation effects generated by 
sonophoresis, iontophoresis or electroporation cannot easily confined to the sole stratum 
corneum, preserving the deeper tissues [1]. Moreover, these enhancement strategies entail 
the development of specific devices easy to handle.  
On the contrary, a biological drug - skin penetrating peptide conjugate can be directly 
loaded in a topical dosage form which generally meets the good patient compliance. 
However, the conjugation leads to a new chemical entity that can have different 
pharmacological and/or toxicological properties with respect to the native drug. To 
overcome this issue, the design of the conjugate should be tuned to obtain a compound 
which maintains its features during the diffusion through the stratum corneum and, at the 
same time, assures the release of the parent drug in the viable epidermis. 
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4. Low Molecular Weight Heparins 
copies: have they to be considered 
generics or biosimilars? 
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Abstract 
 
The protection rights of low molecular weight heparins (LMWHs) are expired or are 
expiring, so the extent and nature of the studies required to obtain a market authorization 
for LMWHs copies represents a hot topic. FDA classifies LMWHs as semisynthetic drugs 
and their copies as generics while EMA views them as biological medicines and 
consequently their copies as biosimilars. Consequently, FDA requires only in vivo 
pharmacodynamic studies, while EMA requires also clinical trials. The current work 
reviews the chemical composition and therapeutic indications of LMWHs available in the 
EU and USA markets in order to discuss the two different approaches. Since LMWHs 
show a high intrinsic variability and a complete characterization is not viable, a 
conservative approach is desirable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The content of this chapter was published in Drug Discovery Today (Minghetti et al. Drug 
Discovery Today 2013, 18 (5/6), 305-311) 
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4.1 Introduction 
 
Low molecular weight heparins (LMWHs) are a family of glycosoaminoglycans widely 
used in the treatment of the thromboembolism prophylaxis in patients undergoing to 
surgical interventions. LMWHs are manufactured by chemical or enzymatic 
depolymerization of unfractionated heparin (UFH) extracted from animal sources.  
Recently, patent rights and supplementary protection certificates of some originator of 
LMWHs have expired or are about to expire, raising the opportunity to develop copies of 
the innovator products, thus boosting the competition among pharmaceutical companies. 
In this scenery, the Marketing Authorisation Application (MAA) can be generally 
handled as an abridged application, submitting a reduced dossier which contains 
sufficient data to assure the same level of quality, safety and efficacy of the originator. 
Nevertheless, the US Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) have two distinct viewpoints on the nature of LMWHs which lead to 
different pathway for granting the MAAs of their copies: LMWHs are classified as semi-
synthetic or biological products by the FDA and the EMA, respectively. Therefore,  EMA 
requires appropriately powered clinical trials to establish comparable efficacy and safety 
between copies and the innovator product. In contrast, the FDA requires only in vivo 
pharmacodynamic studies. The two different approaches have started a thorough debate 
in the scientific community, as demonstrated by the continuous revision and issue of 
guidelines. 
In the present paper, we review the chemical composition and therapeutic indications of 
LMWHs available in the EU and US markets in order to provide useful information to 
discuss the regulatory frameworks of the EMA and the FDA.  
 
4.2 Chemical features and quality requirements of UFH and LMWHs 
 
UFH is a polydisperse mixture consisting of variably sulfated repeating disaccharide units 
which are composed of a glucosamine 1,4 linked to an uronic acid which is represented 
by both its epimers, namely the glucuronic (GlcA) and the iduronic acids (IdoA) (Figure 
4.1). Both monosaccharides can be differently functionalized in the UFH chains: uronic 
acids can be 2-O-sulfated and glucosamine (GlcN) is N-sulfate (GlcNSO3) or N-acetylate 
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(GlcNAc). Moreover, GlcNSO3 may be also O-sulfated in the position 3 and/or 6. The 
GlcNAc residues can be 6-O-sulfated or unsulfated. Hence, the possible presence of four 
different uronic residues and six different glucosamine derivatives makes UHF’s structure 
very complex and variable [1].  
 
 
 
 
Figure 4.1 - Structure of a representative chain of pharmaceutical heparin (adapted from [9]; 
Rabenstein, D.L. (2002) Nat. Prod. Rep. 19, 312–331). 
 
 
 
In animal organisms, UFH is biosynthetized as a proteoglycan and the primer for the 
elongation of the polysaccharide is the neutral trisaccharide xylosyl-galactosyl-galactose 
(Xyl, Gal, Gal). Then, proceeding from reducing to non-reducing end, three different 
domains can be identified on the basis of the abundance of GlcNSO3 and GlcNAc (Figure 
4.1). The first domain, namely NA domain, is mainly constituted of the repeating GlcA-
GlcNAc disaccharide. The NA/NS domain is characterized by the succession of GlcNSO3 
and GlcNAc units. Finally, at the non-reducing end, a region rich in high sulfated 
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disaccharides is found (NS domain). In particular, sequences of trisulfated disaccharides 
(IdoA2SO3-GlcNSO36SO3) seem to be the major constituents [2].  
The NS domain contains the specific pentasaccharide unit responsible of the binding with 
antithrombin III (AT) (Figure 4.1). This interaction determines a conformational change 
in AT resulting in its activation through an increase in the flexibility of its reactive site 
loop [3]. Once activated, AT inhibits the activity of several proteases involved in blood 
clotting, namely factor XIIa, XIa, IXa and the most notably factor Xa. This direct effect 
on AT accounts for most of the increase in inhibitory activity toward factor Xa induced 
by UFH. Nevertheless, it is of marginal importance in thrombin (Factor IIa) inhibition, 
which largely depends on a template mechanism, with both thrombin and AT binding 
adjacently to the same heparin chain (Figure 4.2) [4]. For this reason, the minimum chain 
length required to promote the direct inactivation of thrombin is of about 18 saccharide 
units (Mw > 5,400) [5].  
UFH can be obtained by domestic mammalians used for food by man [6], namely cattle, 
sheep and pigs [7], which relate to differences in composition and functional activities, 
such as AT and thrombin-binding affinities. After the outbreak of the bovine spongiform 
encephalopathy, UFH is currently extracted only from porcine gut and the process-related 
impurities include other sulfate polysaccharides, i.e. chondroitin sulfate and dermatan 
sulfate [8]. 
LMWHs are obtained by chemical or enzymatic depolymerization of UFH and, 
depending on the production method, display different chemical structures at the reducing 
and/or non-reducing end of polysaccharide chains (Table 4.1). They are characterized by 
an average molecular weight less than 8,000 and a polydispersity index ranging 1.1-1.5 
range [9] and consequently, partially lose the ability to inactivate factor IIa. Thus, the 
ratio between anti-factor Xa and anti-factor IIa activities became greater than that of UHF 
[10]. 
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Figure 4.2-Mechanism of action of UFH (a) and LMWHs (b) (adapted from J. Am. Acad. 
Orthop. Surg. 2002; 10, 299–302). 
. 
 
 
An ideal LMWH should differ from UHF only in molecular mass. Nevertheless, 
manufacturing processes alter the structure of the native polysaccharide which can affect 
the clinical properties of LMWHs. Firstly, the cleavage of the chain can occur within the 
pentasaccharide sequence determining a reduction of the pharmacological activity [11]. 
Indeed, in the case of UHF the number of chains containing the pentasaccharide is 
approximately 30%; this percentage decreases to 15–25% in the LMWH chains [12]. 
Moreover, the cleavage process leads to variations in the sulfation degree ratio and the 
formation of unusual end residues which are artifacts of the depolymerization process 
(Table 4.1). As an example, in the case of enoxaparin, five different residues at the 
reducing end and two different residues at the non-reducing end are described in literature 
[13]. Finally, the structural variability of LMWHs with respect to UFH can be further 
increased by the purification process used to isolate the desired polymeric fractions [9].  
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The factors governing the quality of LMWHs are also strictly related to the quality of 
UFH other than to the manufacturing method. After the case of the heparin contamination 
by oversulfated chondroitin sulfate which caused more than 100 deaths in the USA in 
2008 [Information on Adverse Event Reports and Heparin: 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand
Providers/UCM112669], the US and European Pharmacopoeias reviewed their 
monographs. In particular, H-NMR and anion exchange-HPLC emerged as the two main 
robust tools to determine impurities and contaminants in heparin [14]. Both Ph. Eur. and 
USP define the NMR and chromatographic specifications for the identity and purity of 
UFH and the presence of dermatan sulfate and oversulfated chondroitin sulfate. 
Nevertheless, despite the attempt of harmonization of UFH and LMWH monographs, 
several differences still exist. As far as the definition of the UFH potency is concerned, 
the Ph. Eur. method is based on its ability to delay the clotting time of recalcified citrated 
plasma of sheep, while USP introduced a chromogenic anti-factor IIa assay for potency 
assignment. Moreover, USP defined the ratio of anti-factor Xa activity to anti-factor IIa 
activity and added a limit of galactosamine in total hexosamine which is an indirect 
measure of dermatan sulfate and other galactosamine containing impurities. 
In the EU LMWHs have to comply not only the monograph [15], but also additional 
requirements reported in the specific substance monograph (Table 4.1). The Ph. Eur. tests 
for LMWHs include identification by 13C-NMR which provides their fingerprints. The 
structural information is completed with the determination of the molecular weight 
distribution by means of size-exclusion chromatography (SEC) and the quantification of 
the anticoagulant activity using a proper in vitro assay. Among LMWHs, USP reports 
only the monograph of enoxaparin [16] consisting of a complex set of oligosaccharides 
that have not yet fully characterized because of its high structural variability. The 
European and US Pharmacopeia requirements for enoxaparin are essentially the same. 
Nevertheless, the USP monograph describes a specific assay to determine the percentage 
of materials cyclized in a 1,6-anhydro ring at the reducing end of the chain. This 
requirement was probably introduced because this bicyclic structure is recognized to play 
a role in the interaction with AT [17]. This peculiar feature could be also exploited to 
compare enoxaparin produced by different manufactures. 
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Despite several sophisticated analytical techniques for the determination of the saccharide 
sequence of LMWHs as well as specific assays for the evaluation of their pharmacological 
activity are available, the complexity and the variability of these compounds require a 
continuous research for the development of new and more sensitive assays. In 
confirmation of that, a workgroup with the function to collect and harmonize the 
knowledge of the international experts on this topic has been formed and in UE the 
general monograph of LMWHs is still under revision as well as the enoxaparin, tinzaparin 
and nadroparin ones [http://www.edqm.eu/en/european-pharmacopoeia-work-
programme-EDQM-607.html].
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Table 4.1- Main chemical characteristics of LMWHs currently available in UE and US markets. 
Depolimerization 
method 
LMWH 
(market) 
Representative end 
residues 
Average 
Molecular 
weight 
Anti- 
Xa/IIa 
ratio 
Degree of 
sulfation 
Pharmacopeia 
Specific Assays 
References 
Deaminative 
cleavage 
(nitrous acid) 
Nadroparin 
(UE) 
Non reducing: 2-O-sulfo-
ɑ-L-idopyranosuric acid 
 
Reducing: 6-O-sulfo-2,5-
anhydro-D-mannitol 
4,300 
(range 3,600-5,000) 
2.5-4 about 2.5 
Ethanol; 
N-NO groups; 
Free sulfates. 
[34] 
Dalteparin 
(UE and US) 
6,000 
(range 5,600-6,400) 
2.5-4 1.8 -2.5 
Nitrite 
Boron; 
[35] 
Reviparin  
(UE) 
3,900 
(range 3,000-4,500) 
3.6-6.1 2-2.6  [36, 37] 
(isoamyl nitrite) Certoparin 
(UE) 
3,800 1.5-2.5 2  [36] 
β-eliminative 
cleavage 
(benzilation and 
alkaline treatment) 
 
Enoxaparin 
(UE and US) 
Non-reducing: 
4-enopyranose uronate 
 
Reducing: 1,6-anhydro 
derivate 
4,500 
(range 3,800-5,000) 
 
3.3-5.3 2-2.5 
Benzyl alcohol content 
% oligosaccharide 
chains that are 
cyclized in 1,6-
anhydro ring 
[16, 38] 
(alkaline treatment 
with a quaternary 
ammonium salt) 
Bemiparin 
(UE) 
__ 
3,600-3,800 
 
8.1 -- -- [39, 40] 
Enzymatic treatment 
(heparinase) 
Tinzaparin 
(UE and US) 
Non reducing end: 2-O-
sulfo-4-enepyranosuric 
acid 
 
Reducing end: 2-N,6-O-
disulfo-D-glucosamine 
6,500 
(range 5,500-7,500) 
 -- - [41] 
Radical-catalysed 
depolymerization 
with hydrogen 
peroxide and a 
cupric salt 
Parnaparin 
(UE) 
Reducing end: 2-O-sulfo-
ɑ-L-idopyranosuric acid 
 
Reducing end: 2-N,6-O-
disulfo-D-glucosamine 
5,000 
(range 4,000-6,000) 
 
1.5-3 -- Copper [42] 
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4.3 Therapeutic indications of LMWHs 
 
Most of the LMWHs are indicated for the prophylaxis of deep vein thrombosis (DVT) in 
patients undergoing orthopaedic or general surgery and the treatment of DVT [18-23]. 
They are the anticoagulant of choice for the prevention of DVT after major orthopaedic 
surgical procedures. 
Dalteparin, enoxaparin and nadroparin in combination with acetylsalicylic acid are also 
effective for the prophylaxis of ischemic complications in patients with unstable angina 
and non-Q-wave myocardial infarction [18; 19; 20]. In particular, enoxaparin has 
consistently been demonstrated to have a superior efficacy than other LMWHs in patients 
with acute coronary syndrome [24]. Dalteparin, enoxaparin, nadroparin and bemiparin 
are also indicated for the prevention of clotting in the extra corporeal system during 
haemodialysis and hemofiltration in patients with acute renal failure or chronic renal 
insufficiency [18; 19; 20; 23]; Enoxaparin is also used for the prophylaxis of venous 
thromboembolism (VTE) in non-surgical patients with severely restricted mobility during 
acute illnesses, such as cardiac insufficiency, respiratory failure, severe infections or 
rheumatic disease and for the treatment of acute DVT with or without pulmonary 
embolism [18]. Enoxaparin is the leading LMWH with the widest range of therapeutic 
indications. Indeed, the administration of enoxaparin to treat acute ST-segment elevation 
myocardial infarction in patients receiving thrombolysis and being managed medically or 
with percutaneous coronary intervention was demonstrated to be effective in reducing 
mortality and ischaemic and bleeding end points [25].  
The FDA approved the use of dalteparin for the management of symptomatic VTE 
(proximal deep vein thrombosis and/or pulmonary embolism) in cancer patients [26].  
The design and extent of the clinical studies can have an effect on  the indications 
contained in the Summary of Product Characteristic information. Thus, clinical 
indications for the same product may differ slightly in the various countries where it has 
been approved, as exemplified in Table 4.2. This incoherence can be observed  not only 
between  US and European markets, but also between  single countries in the EU, 
probably due to the fact that LMWHs were marketed in the early ’90s before Regulation 
2309/93/CEE coming into effect  and MAAs were presented independently in each 
country.  
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Table 4.2-Clinical indications of LMWHs approved in USA, Italy and United Kingdom. 
 FDA IT UK 
Enoxaparin 
-Prophylaxis of DVTa in patient undergoing orthopaedic or general 
surgery or medical patients with bedridden due to acute illness 
-Treatment of acute DVT with or without PEb 
______ 
-Prevention of clotting in the extracorporeal 
system during hemodialysis 
-Treatment of unstable angina and non-Q 
wave myocardial infarction, administered 
concurrently with aspirin 
-Prophylaxis of 
ischemic complications 
of unstable angina and 
non-Q wave myocardial 
infarction 
______ 
-Treatment of 
STEMIc 
managed 
medically or 
with subsequent 
PCId 
Tinzaparin 
-Treatment of acute 
symptomatic DVT with 
or without PE when 
administered in 
conjunction with 
warfarin sodium 
-Not available on the 
market 
-Treatment of 
DVT and of PE 
Dalteparin 
-Prophylaxis of DVT in patient undergoing 
orthopaedic or general surgery 
______ 
______ -Treatment of acute DVT 
-Prophylaxis of 
ischemic complications 
of unstable angina and 
non-Q wave myocardial 
infarction 
-Extended treatment of 
symptomatic VTEe to 
reduce the recurrence in 
patients with cancer 
-Prevention of clotting 
in the extracorporeal 
system during 
hemodialysis 
-Treatment of unstable 
angina and non-Q wave 
myocardial infarction, 
administered 
concurrently with 
aspirin 
-Treatment of 
PE 
-Treatment of 
DVT with PE 
Data extrapolated from [18; 19; 25; 26; 43; 44; 45; 46] 
a DVT: deep vein thrombosis; b PE: pulmonary embolism; c STEMI: acute ST-segment 
elevation myocardial infarction; d PCI: percutaneous coronary intervention; e VTE: venous 
thromboembolism 
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4.4 Regulatory aspects of the US-FDA 
 
As mentioned, the FDA considers LMWHs as semisynthetic drugs and, therefore, the 
generic drug products can be marketed after the approval of an Abbreviated New Drug 
Application (ANDA), demonstrating bioequivalence, the same active ingredient(s), route 
of administration, dosage form, strength, conditions of use and labelling as the originator 
[27].  
In July 2010, the FDA approved the first copy of enoxaparin sodium and nowadays two 
generic versions are available on the market. This decision of the American regulatory 
agency was not free of blame. Indeed, the Marketing Authorization Holder (Aventis 
Pharmaceuticals) presented a petition to FDA asking to stop the approval of  the generic 
version of its product, unless the ANDA applicant completely characterized  the active 
substance, even  in terms of polysaccharide chains, using the identical production process 
employed for the synthesis of the originator product or carrying out proper clinical trials. 
The  request was rejected by the FDA on the basis  that even  the brand product shows a 
certain level of batch to batch variability and  that  no regulation requests that the process 
parameters assessed by the two competitors  should be  identical. It is sufficient that the 
applicant uses the same depolymerisation method (β-eliminative cleavage) employed by 
the Marketing authorization Holder. 
The evaluation of the equivalence between the originator and generic products relies on 
the qualitative and quantitative analysis of the generic product in comparison to different 
batches of the originator. The same level of variability between the two products is 
considered as an index of sameness of the active substances. In support of this thesis, 
FDA also stated that the use of generic versions of UFH has not been associated to any 
significant increase of side effects despite the less restrictive criteria for the ANDA 
approval [Generic Enoxaparin Questions and Answers: 
http://www.fda.gov/Drugs/Drugsafety/PostmarketDrugSafetyInformationforPatientsand
Providers/ucm220037.htm]. Following this approach, the FDA scientists established five 
criteria to assure that the generic product drug contains the same active ingredient as its 
originator [28].  
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Criterion 1: equivalence of heparin source material and mode of depolymerization 
Porcine intestinal mucosa is the only heparin source authorized by the FDA. It can be 
expected that UFH obtained from the same source materials contains a similar distribution 
of the disaccharide building block sequences. 
The mode of depolymerization does not perturb the conformation of the “natural” 
disaccharide building blocks of UFH, but generates a modification of disaccharide units 
at the terminal ends. Therefore, this criterion is based on the estimation of the same 
chemical selectivity for UFH of equivalent mode of depolymerization used in the 
manufacturing process. As a consequence, the modification at the terminal end of the 
generic and the originator are considered very similar.  
 
Criterion 2: equivalence of physicochemical properties 
This criterion is used to ensure that the molecular weight distribution of enoxaparin in the 
generic drug product is equivalent to that in the originator.  
In addition to conventional SEC, complementary analyses termed “chain mapping” by 
CTA-SAX chromatography, MALDI-MS, GPC-ESI-MS, or RPIP-ESI-MS are required 
to provide a high resolution fingerprint profile of the oligosaccharide chain lengths and 
demonstrate the equivalent distribution in the generic drug product and the originator. 
 
Criterion 3: equivalence in disaccharide building blocks, fragment mapping and 
sequence of oligosaccharide species 
This comparison looks at the products' molecular nature: besides confirming the presence 
of a pharmacologically important 1,6-anhydro ring at the ends of 15–25% of enoxaparin 
chains, the FDA looks at the spectrum of disaccharide building blocks and the 
oligosaccharide lengths and sequences-factors affected by the temperature, 
depolymerization time and other conditions of preparation [29]. Analyses of enoxaparin 
or partially digested enoxaparin with purified heparinases are carried out by using 
capillary electrophoresis, RP-HPLC, SAX-HPLC, mass spectroscopy and NMR 
spectroscopy.  
If even this criterion is met, there are substantial supporting evidences that the generic 
drug product is the same as originator. 
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Criterion 4: equivalence in biological and biochemical assays 
To demonstrate equivalent anticoagulant activity in vitro and in vivo, the FDA requires 
the studies of relevant markers, such as activated partial thromboplastin time (aPTT), 
heptest prolongation time, anti-factor Xa activity, anti-factor IIa activity and anti-factor 
Xa/anti-factor IIa activity ratio. 
 
Criterion 5: equivalence of in vivo pharmacodynamic profile 
The comparison of pharmacodynamic profiles is based upon measurement of anti-factor 
Xa and anti-factor IIa profiles in human health volunteers. Moreover, the FDA also 
requests to conduct immunogenicity tests (i.e. Heparin Induced Thrombocytopenia II, 
HIT II). 
Thus, if the five criteria are complied with, the generic enoxaparin will have the same 
active ingredient as the originator. According to the FDA approach, the first three criteria 
ensures that the heparin source material, the chemical reaction used in the manufacturing 
process, and the structure (average molecular weight, polydispersity and chemical 
composition of the terminal ends) of enoxaparin in the generic drug product is equivalent 
to that in the originator. The fourth and fifth criteria assure that the generic enoxaparin 
sodium has the same degree of anticoagulant activity and safety as originator.  
 
4.5 Regulatory aspects of the EMA 
 
The EMA defines LMWHs as biologics regarding their copies as biosimilars. Therefore, 
in order to obtain the MA, the applicant has to demonstrate the equivalence  of biosimilar 
and originator, in terms of effectiveness and safety, by the “comparability exercise” on 
the basis of clinical trials [30]. The number and extent of comparability studies required 
to grant a MA are detailed in the guidelines issued by the Committee for Medicinal 
Products for Human Use (CHMP). According to the “Guideline on similar biological 
products containing LMWHs” adopted in 2009 [31], the EMA expects that all LMWHs 
products meet the physicochemical specifications present in the Ph. Eur. monographs. 
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Non-clinical requirements 
A number of comparative bioassays including evaluations of the anti-factor Xa and anti-
factor IIa activity should be carried out to determine relevant pharmacodynamic effects 
of LMWHs and demonstrate the similar activity between the copies and the originator. 
The EMA requires also the assessment of the toxicology in a relevant species, e.g. rats, 
in accordance with the “Note for guidance on repeated dose toxicity” [32] for at least 4 
weeks. In contrast, studies on the safety pharmacology, reproduction toxicology, 
mutagenicity and carcinogenicity are not routine requirements for non-clinical testing of 
LMWH biosimilars. 
 
Clinical requirements 
These studies should be performed to compare the pharmacodynamic and 
pharmacokinetics parameters of the copy and the originator products. The manufacturer 
could use pharmacodynamic activities (e.g. anti-factor Xa and anti-factor IIa, tissue factor 
pathway inhibitor) as surrogate markers for LMWHs circulating concentrations. The 
study of these parameters should be performed in a randomized two way crossover study 
in healthy volunteers after the administration of a single subcutaneous dose and other 
routes of administration, if the originator is authorized. 
Since it is assumed that a univocal correlation between pharmacodynamic parameters and 
clinical effects does not exist, the EMA requires at least one adequately powered, 
randomised, double-blind, parallel group clinical trial in the setting of prevention of VTE 
or arterial thromboembolism or treatment of VTE. The clinical trial should be performed 
in the most sensitive, highest VTE risk population, such as in patients undergoing elective 
major orthopaedic surgery. 
This study is required to demonstrate that the copy exhibits equivalent therapeutic 
efficacy to the reference product. The most relevant endpoints, namely DVT, pulmonary 
embolism and VTE-related death, should be analyzed by the most advanced technologies 
and all data should be evaluated by a central independent and blinded committee of 
experts, using pre-specified limits. 
The EMA also requires a comparative study demonstrating similar safety profile of the 
biosimilar versus the reference product analyzing the different type, frequency and 
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severity of the adverse reactions. Finally the applicant has also to perform an analysis for 
the detection of HIT II [31]. 
 
 
4.6 Concluding remarks 
 
In the clinical practice LMWHs have been demonstrated to be superior to UFH as 
antithrombotic agents because they have a much longer half-life and exhibit a lower 
incidence of HIT II. Moreover, unlike to UFH, a frequent monitoring is not needed to 
adjust the dose. However, LMWHs have different pharmacokinetic and 
pharmacodynamic profiles due to the specific depolymerization processes and, therefore, 
they cannot be considered interchangeable. Indeed, the peculiar manufacturing methods 
lead to a greater structural variability than UFH. At the same time, the high molecular 
complexity of LMWHs prevents a complete chemical and physical characterization 
which is essential to predict the biological activity. This intricate background is further 
complicated by the expiration of protection rights of some LMWHs which raises the 
opportunity to develop copies. EMA and FDA adopted different approaches to grant 
MAs. In particular, the EMA considers LMWHs as biosimilar products and recommends 
phase III clinical trials for the comparability exercise. On the contrary, the FDA, 
classifying LMWHs as semisynthetic drug products, does not require such trials, but only 
the determination of pharmacodynamic profiles in healthy human volunteers. The FDA 
also asserts that the individuated five criteria are more sensitive to evidence differences 
between two generic LMWHs than the clinical studies recommended in the EMA 
guideline. In support of FDA’s approach, it should be mentioned that the quality 
requirements are more restrictive in US than UE. As a matter of fact, Ph. Eur. lacks  
specific assays to determine some relevant structural elements such as the percentage of 
1,6-anhydro ring at the reducing end of the enoxaparin chains which, on the contrary, are 
included in USP. Nevertheless, taking into account the intrinsic variability of LMWHs 
obtained by the same depolymerization method and the objective current unfeasibility of 
a complete characterization of these complex semisynthetic compounds of biological 
origin, a conservative approach is desirable since it guarantees a higher level of safety for 
the patient’s health. Reasonably, the reduction of the number of clinical studies required 
Chapter 4 
93 
 
by the EMA supported by a more specific chemical and analytical characterization is the 
direction to be pursued in order to ease the introduction on the market of LMWHs copies 
with a safety and efficacy profile comparable to that of the originator. In July 2011, the 
EMA published a concept paper on the revision of its LMWH specific guideline 
suggesting the possibility to reduce clinical data requirements. The draft guideline should 
be released for consultation  during the course of  2012 [33]. The definition of the extent 
of clinical studies required for the MA in UE could benefit from  the experiences that will 
be matured in US market, and the  availability of pharmacovigilance data. 
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Final Remarks 
 
This PhD thesis proposed to investigate the physicochemical parameters that rule the 
permeation through human skin of GAGs, with particular focus on HA and heparins. 
The overall experimental data confirmed that Mw represents a fundamental factor in 
determining the permeability properties also of such polysaccharides. Indeed, in in vitro 
studies performed using human epidermis as membrane, HA at “low Mw” (6.7 KDa) 
showed a greater penetration than the corresponding polymer at higher Mw (Chapter 1). 
Similarly, LMWHs sodium salts permeated to a larger extent with respect to UFH and a 
good correlation between Log Mw and Q24 was found for LMWHs sodium salts (Chapter 
2). However, the key parameter that drives the permeation of such macromolecules 
through the skin resulted to be the polymer flexibility, which allows the compounds to 
adapt to the different skin environments. In fact, the introduction of sulfate groups on HA 
chains, causing the disruption of the helical motif, led to less ordered structures, which 
were able to cross the skin to higher extent compared to unsubstituted HA, despite their 
increased polarity (Chapter 1). Accordingly, the presence of divalent cations in LMWHs 
solution, causing the reduction of the chain flexibility through the formation of 
intramolecular chelates, negatively affected the skin permeability properties of calcium 
nadroparin (Chapter 2). 
Furthermore, both classes of polysaccharides investigated (HA and heparins) 
demonstrated to interact with stratum corneum components, in particular keratins, as 
confirmed by confocal miscroscopy images (HA, Chapter 1) and ATR-FTIR spectra 
(UFH, Chapter 3), suggesting that the diffusion through human stratum corneum 
occurred mainly by transcellular route.  
Since the physicochemical features of these polysaccharides (hydrophilicity, negative 
charge and high Mw) precluded a significant diffusion through the human epidermis, the 
phage display technique was exploited to screen a skin penetrating peptide which could 
enhance the skin permeation of such molecules, allowing their transdermal delivery. The 
in vitro screening allowed to identify a neutral peptide, DRTTLTN, which resulted to be 
able to increase the permeation of UFH through the skin after chemical conjugation 
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(Chapter 3). These results demonstrated the suitability of skin penetrating peptides to 
enhance also the transdermal delivery of polysaccharide macromolecules. 
 
The analysis of the scientific literature related to LMWHs evidenced also a critical and 
debated regulatory topic raised from the expiration of protection rights of brand LMWHs 
and the incoming introduction on the European market of their medicinal copies. The 
classification of these copies resulted to be particularly controversial since LMWHs are 
produced by chemical synthetic strategies involving, however, the depolymerization of a 
drug obtained from biological sources (UFH). This dual characteristic led EMA and FDA 
to adopt two different approaches for the classification and, consequently, the regulation 
of non-proprietary LMWHs. In fact, in the FDA opinion prevailed the synthetic origin of 
LMWHs and the American agency classified the copies as generics, whereas EMA 
considered more relevant the biological nature of the precursor thus defining LMWHs 
copies as biosimilars. The need to deal with this hot regulatory topic boosted the in depth-
analysis of the chemistry of LMWHs and the assays provided for their proper 
characterization and led to the publication of a paper on a peer-reviewed journal (Chapter 
4).  
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6BrCaQ nano-liposomes as tool to target 
breast and prostate cancer cells 
 
 
1. Introduction 
 
Breast and prostate cancers are the two tumors with the major incidence in women and 
men respectively and are leading causes of mortality in developed countries. Although 
they develop in organs anatomically and physiologically different, they share many 
similar biological features, first the hormonal-dependence [1]. Hence, the first line 
treatment (after surgery) for these types of cancer is the hormonal therapy, which relies 
on the inhibition of the biosynthesis of steroids or the block of the receptors activity. 
However, also steroid receptor-positive cancers (two-thirds of breast cancers) develop a 
hormonal resistance leading to the failure of the therapy based on anti-oestrogen and anti-
androgen drugs [2, 3]. Therefore, an intensive research is aimed to select alternative 
targets along the different pathways involved in the pathogenesis of cancer [4].   
Heat shock protein 90 (Hsp90) is a molecular chaperone (90kDa) which modulates the 
biological action of several client proteins allowing their folding in the active 
conformation through a cycle regulated by the binding and the hydrolysis of ATP and by 
other co-chaperons [5]. Inhibitors of Hsp90 lead to the degradation of client proteins by 
the ubiquitin-proteasome system. At date, at least 200 client proteins of Hsp90 have been 
identified and, since most of them are oncoproteins, Hsp90 is considered a powerful target 
in cancer therapy [6]. Although this chaperone is ubiquitously distributed, it represents a 
selective target, since heat shock proteins are overexpressed in cancer cells in response to 
different stressful stimuli (such as heat, hypoxia and acidosis) which occur in tumor 
environment. Moreover, it was demonstrated that Hsp90 from cancer cells shows a higher 
affinity for the inhibitors with respect to that present in normal tissue [7, 8]. This could 
limit the risk of side secondary effects for the Hsp90 inhibitors, which constitutes the 
major concern of the anticancer therapy. 
Appendix 
102 
Hsp90 is a homodimer composed of two well conserved N-terminal and C-terminal 
residues, a middle domain with the binding site of client proteins and a charged region of 
different length which follows the N-terminal domain [5, 9]. The C-terminal domain is 
essential for Hsp90 dimerization and contains a secondary site of binding of ATP 
(recently hypothesized) along with a polypeptide involved in the recognition and binding 
of co-chaperons. The antibiotic coumarin novobiocin (Nvb) was the first compound 
identified to weakly bind to this secondary ATP pocket inducing the degradation of Hsp90 
client proteins. Once discovered the activity of Nvb, attempts have been made to develop 
derivatives with greater anti-cancer effect [10]. In fact, the C-terminal inhibitors are 
supposed not to induce a heat-shock response (induction of “pro-cancer” Hsp70 and 
Hsp27), which may account for the resistance to the N-terminal inhibitors contributing to 
the limits of the clinical trials [11].  
In this context, Audisio and coworkers, have synthesized a series of quinolein-2-one 
derivatives of Nvb which exhibited a greater affinity to the C-terminal domain of Hsp90 
compared to the natural antibiotic. Among those, the 6-bromo-3-[4-
methoxyphenylcarboxamide]-quinolein-2-one, 6BrCaQ (Figure 1), resulted to be the 
most effective as anti-proliferative agent in different cancer cell lines (Figure 2). It caused 
the arrest of MCF-7 breast cancer cells in cell cycle in vitro and was able to induce the 
apoptosis both through the intrinsic and extrinsic pathways [6].  
 
 
 
 
Figure 1- Chemical structure of 6BrCaQ [6] 
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Figure 2- Antiproliferative effect of Nvb and derivatives on MCF-7 breast cancer cells [6] 
 
 
 
Despite its promising efficacy as anticancer agent, 6BrCaQ is characterized by a very 
poor solubility in water (70 mg/L), which prevents its parenteral administration in vivo. 
The encapsulation in liposomes is a well-established expedient to enable the 
solubilization of hydrophobic drugs [12]. Moreover, liposomes have been extensively and 
successfully exploited to target cancer since they can passively accumulate in solid 
tumors through the so-called “enhanced permeability and retention effect (EPR) [13]. 
Indeed, in spite of slight differences in the various types of cancer, tumors present a leaky 
vasculature in which endothelial gaps have larger pores compared to a normal 
endothelium (100-780 nm against 5-10 nm of diameter). Then, colloidal carriers 
preferentially extravasate into tumor interstitium where they are retained due to the lack 
of an effective drenage system [14]. This phenomenon, which depends exclusively on the 
physiologic features of the tumor tissue, is known as “passive targeting” and requires 
liposomes having size ideally less than 200 nm for a proper extravasation [15]. Along 
with nano-sized dimensions, stealth® properties represent the other paradigm of cancer 
targeting. In fact, liposomes could be degraded by the reticuloendothelial system (RES) 
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through opsonization before reaching the target. The clearance by RES is prevented by 
grafting hydrophilic moieties, mainly polyethylene glycol (PEG) chains, on the liposome 
surface (Stealth® liposomes) which obstacle the absorption and binding of opsonins 
enabling the carriers to persist longer in the bloodstream [16]. Long circulating liposomes, 
once accumulated in tumor, can deliver the drug directly into the cells (after 
internalization) or in the extracellular fluid, improving the narrow therapeutic index of 
the anticancer drugs [16].  
 
This work aimed to encapsulate 6BrCaQ in Stealth® nano-liposomes to overcome the poor 
solubility of the drug and enable the in vivo evaluation and administration. The 
composition of liposomes (Egg phosphatidylcholine (EPC), 1,2-distearoyl-snglycero-3-
phosphoethanol-amine-N-methoxy-[poly-(ethylenglycol)-2000] (DPSE-PEG2000) and 
cholesterol (Chol)) was selected on the basis of previous promising results obtained with 
the encapsulation of a hydrophobic anti-oestrogen drug [17]. Liposomes were 
characterized from a technological point of view, by determining size, zeta potential, 
encapsulation and purification efficiency, as well as physical stability during both storage 
and use in culture. The drug leakage in physiological conditions was also evaluated, 
considering the lipophilic nature of the drug (which can determine a prompt release 
through the lipid bilayer) and the use of phospholipids with low transition temperature 
(Tm of EPC= -2 °C). The biological activity of liposomes was evaluated by using 
metastatic breast and prostate cancer cells in culture, in comparison to that of the non-
encapsulated drug. The effect on cell viability and on cell proliferation was investigated 
by MTS assay and flow cytometry. The possible liposomes-cells interaction was 
evaluated by using fluorescent lipids and confocal microscopy. Finally, the anti-
metastatic potential of the formulation was determined by carrying out in vitro migration 
assays. 
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2. Materials and Methods   
 
2.1. Materials 
 
6BrCaQ was synthesized in the laboratory BioCIS UMR 8076 (Faculté de Pharmacie, 
Université Paris-Sud 11). Stock solutions (10 mM) were prepared in chloroform or 
dimethylsulfoxide (DMSO) depending on the further application (formulation or use in 
cell culture, respectively). EPC, DPSE-PEG2000 and rhodamine-labeled 
phosphatidylethanolamine (Rho-PE) were purchased by Avanti Polar Lipids Inc., 
Birmingham, USA. Chol was purchased by Sigma Aldrich (St. Quentin-Fallavier, 
France). Chemokine CCL2 (Rh-MCP-1) was purchased by Shenandoah Biotechnology 
Inc. RPMI 1640, Leibovitz’s L-15 medium, trypsin/EDTA solution were purchased by 
Lonza. All other chemicals were reagent grade. 
 
2.2. Preparation of liposomes 
 
Liposomes were prepared by the conventional thin film hydration method, accordingly to 
a procedure previously described [17].  
Briefly, lipids (EPC/Chol/DSPE-PEG2000 64:30:6 molar ratio) were dissolved in 
chloroform to obtain a final concentration of 50 mM and 6BrCaQ (0.5 mM in chloroform) 
was added and mixed with lipids. For the preparation of fluorescent liposomes, 1% Rho-
PE was added to the lipid mixture. After evaporation of the organic solvent under reduced 
pressure (BUCHI rotary evaporator, 80mbar, 25°C), the dried film was rehydrated with 3 
mL of Hepes buffer (Hepes 10 mM, NaCl 145 mM, pH 7.4). The resulting multilamellar 
vesicles (MLVs) were extruded (extruder Whitley, Lipex, Vancouver, Canada) 
sequentially through 0.2 μm (3 passages) and 0.1 μm (5 passages) polycarbonate 
membranes (Millipore, USA). 
Unincorporated 6BrCaQ was removed by ultracentrifugation at 40,000 g for 17 h at 4°C 
(Rotor 50.4 Ti, Beckman Ultracentrifuge, USA). Liposomes were stored at 4°C under 
atmosphere of argon until their use. 
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2.3. Physicochemical characterization of liposomes 
 
Liposomes were characterized in terms of size and zeta potential by dynamic laser 
scattering (DLS), using a Zetasizer 4 Malvern (Malvern Inst., UK). For size measurement, 
liposomes samples were diluited 1:10 in Hepes buffer. Each measure was performed in 
triplicate with an angle of detection of 173°. The zeta potential was measured after proper 
dilution of the liposomes suspension in deionized water. Also in this case each result 
corresponds to the mean of three independent determinations.  
Lipids content was assayed by using a specific kit for phospholipids dosage Biolabo. This 
relies on an enzymatic method, which allows the transformation of lipids in colored 
compounds able to absorb the UV light at 500 nm and it is specific for PC. 
Drug encapsulated in liposomes was quantified by spectrofluorimetry (Ex=340 nm, 
Em=390 nm) (Hitachi F-2000 spectrofluorimeter) after dilution 1:100 of the samples in 
DMSO/Hepes buffer (99:1, v/v), to break the lipid vesicles. The concentration of the drug 
was estimated using a calibration curve built in the range 0.1-10 µM (R2=0.994). For 
higher concentrations, the process of fluorescence quenching was observed. 
Any interference from lipids or DMSO/Hepes buffer was observed at these wavelengths.  
The encapsulation efficiency (EE%) was calculated as following:  
𝐸𝐸% =
𝐶𝐿
𝐶𝐼
 𝑥 100 
where CL is the 6BrCaQ concentration in purified liposomes and CI is the concentration 
of 6BrCaQ in the initial suspension. The efficiency of the purification method was 
assessed by measuring the lipid content before and after ultracentrifugation and according 
to the equation:  
 
Purification efficiency: 
amount of lipids in purified liposomes  
total amounts of lipids
× 100 
 
The physical stability of liposomes was evaluated both in storage conditions and in RPMI 
1640 medium. In the first case, the size of liposomes was measured immediately after 
their preparation and after 2 and 3 months of storage in glass vials at 4°C. 
To investigate the stability in culture environment, liposomes were suspended in RPMI 
1640 and incubated at 37°C under continuous stirring for 72 h, the longest time of 
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incubation tested during the in vitro studies. Then, an aliquot was withdrawn and particle 
size distribution was measured by DLS (as described earlier) against the culture medium 
alone, to assess the contribution of proteins. The analysis was performed in triplicate. 
Drug-leakage studies at physiological temperature were performed as well, to estimate 
the ability of the selected formulation to retain the entrapped drug. Briefly, liposomes at 
concentration of 20 µM were suspended in PBS. 200 µl were withdrawn and assayed by 
spectrofluorimetry to determine the experimental starting concentration. The suspension 
was incubated at 37°C under agitation for 72 h and 120 h respectively. At these intervals 
of time, samples were collected and ultracentrifugated (40,000 g, 17 h, 4°C) to precipitate 
liposomes from the suspension. Both supernatant and precipitate were assayed for drug 
quantification. A solution of free drug at the same concentration was prepared and tested 
in parallel to exclude the precipitation of crystals of the free drug in the pellet during 
ultracentrifugation.  
 
2.4. Cell culture 
 
In vitro anti-tumor activity of 6BrCaQ encapsulating liposomes was evaluated on two 
different cancer cell lines: PC3 and MDA-MB-231 (ATCC, Molsheim, France). PC3 is a 
human prostatic carcinoma cell line derived from bones metastasis. It was cultured in 
RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
and 0.5% antibiotics (penicillin/streptomycin 50 IU/mL and 50μg/mL respectively). 
Decomplemented FBS was obtained by destroying the complement proteins by heating 
FBS at 56°C in a water bath. 
MDA-MB-231 are mammary/glad cancer cells derived from pleural effusion. They were      
cultured in Leibovitz’s L-15 medium supplemented with 15% decomplemented FBS, 1% 
glutamine and 0.5% penicillin/streptomycin, in presence of 22 mM sodium bicarbonate 
allowing the culture of the cells in a CO2 atmosphere. Cells were maintained at 37 °C and 
5% CO2 in humidified atmosphere. 
 
2.5. Biological activity in vitro 
 
Cell viability was assessed using CellTiter 96 Aqueous One Solution® (Promega, 
Charbonni`eres, France). The method relies on the bioreduction of MTS [3-(4,5-
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dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] 
by NADPH or NADH produced by dehydrogenase enzymes in metabolically active cells 
to form a colored formazan product which is soluble in tissue culture medium. 
Cells were seeded in a 96 wells plate (2.5 x 103 PC3 cells/well and 7.5 x 103 MDA-MB 
231 cells/well) and let to adhere to the plate for 24 hours. Then they were treated for 
different times with 6BrCaQ free or liposomes at different concentrations and incubated 
at 37°C and 5% CO2. DMSO (the solvent for the free drug) and unloaded liposomes (at 
the same lipid concentration of loaded ones) were used as controls. At the end of the 
treatment, 20 µL of reactive were added in each well and the absorbance of the samples 
at 492 nm was recorded using a 96-well plate reader. The values were corrected by 
subtracting the absorbance of the control wells containing cell-free medium. The 
percentage of viability was calculated as the ratio between the absorbance of the treated 
cells and that of the control (untreated cells). 
The cell cycle was analyzed by flow cytometry. PC3 cells were seeded (30,000 cells/cm2) 
in a 6 wells plate and let to grow for 24 h, then treated (5 μM drug) for 24 or 72 h. Cells 
were washed in PBS and detached by adding 1 mL of trypsin at 37°C. 
2 x 105 cells were precipitated by centrifugation at 500 rpm for 10 min, washed twice in 
cold PBS and resuspended in 200 µL of PBS, which were added drop by drop to 800 µl 
of absolute ethanol to permeabilize cells. Cells were stored at -80°C until the day of the 
analysis. Fixed cells were precipitated by centrifugation (2000 rpm, 10 min) to remove 
ethanol and suspended in PBS containing 100 µg/ml RNase A and 10 µg/ml propidium 
iodide. After incubation for 30 min at 37°C, the distribution of cells in the cell cycle was 
analyzed with a BD Accuri™ C6 flow cytometer (BD Biosciences). 
 
2.6. In vitro liposome uptake 
 
The uptake of liposomes into the cells was studied by confocal microscopy. Cells were 
seeded in a 8 wells system Labteck mounted on a microscope slide (1.6 x 104 cells for 
MDA-MB-231 and 8 x 103cells for PC-3). After 24 h of adherence, the culture medium 
was replaced by a suspension (in culture medium) of fluorescent liposomes containing 
6BrCaQ (5µM), for a time of exposure varying from 30 min to 4 h. Cells were washed 
with cold PBS, fixed with 2% formaldehyde containing 0.5 μg/ml of Hoechst 33342 (for 
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30 min) and washed again three times with cold water. Samples were covered with a glass 
slide with the help of Vectashield HardSet Mounting Media to preserve the fluorescence. 
Confocal imagines were collected using a X63 oil immersion objective at 488 nm from 
an argon laser using a Zeiss LSM 510 confocal microscope. Untreated cells were analyzed 
in parallel as control. 
 
2.7. Wound healing assay 
 
The migration of PC3 cells in vitro, as index of their metastatic potential, was assessed 
by wound healing assay. Briefly, cells were seeded in a µ-slide 8 wells (IBIDI) and grown 
until confluence in complete medium. 
As the monolayer was formed, the well was scratched vertically by using a 200 µL pipette 
tip. The medium containing the cellular debris was removed and replaced by the treatment 
in 1% FBS RPMI 1640. Culture medium depleted of serum was used in this assay to limit 
cell proliferation and better observe the effect of the treatment on cell motility. 
Chemokine CCL2 (40 ng/mL) was added in each well since it is well known its 
fundamental role in promoting prostate cancer cell chemoattraction, proliferation, and 
survival [18]. Cells were incubated at 37 °C in atmosphere with 5% CO2 and their 
migration in the direction of the wound was followed with a microscope (AxioObserver 
Z1, Carl Zeiss, German) equipped with a CoolSnap HQ2 CCD camera (Photometrics, 
Tucson, USA), by taking a picture each h during 24 h. 
The test was performed in duplicate by using two distinct batches of liposomes. 
Migrating cells were counted by using ImageJ analysis software. A region-of-interest 
(ROI) within the limits of the wound was selected and the number of cells migrated in 
this area at each time was measured automatically. The migration profiles were obtained 
by plotting the number of cells migrated per mm2 as a function of the time.  
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3. Results and Discussion 
 
3.1. Physicochemical characterization of liposomes 
 
The main physicochemical parameters of 6BrCaQ encapsulating liposomes are reported 
in Table 1. The negative value found for the zeta potential is in agreement with the results 
described in literature for the same formulation [17]. Slight differences are congruent with 
the different ionic strength of the vehicles used for samples dilutions (NaCl 1 mM and 
water respectively). 
 
 
Table 1-Main physicochemical characteristics of 6BrCaQ loaded liposomes 
Mean Size (nm) 
(+/-SD) 
pdI 
Zeta potential (mV) 
(mean+/-SD) 
EE % 
Purification 
efficiency (%) 
94.27±36.53 0.10 -14.53 ±7.08 63.74±10.61 88.25±14.78 
 
 
Liposomes resulted to be stable after storage at 4°C for 2 and 3 months since any 
increment of size was observed by dynamic laser scattering (Table 2). Hence, the zeta 
potential, even if lower than the theoretical minimal value required for stability (30 mV 
in absolute value), along with the steric interaction between PEG2000 chains, caused the 
repulsion of vesicles, preventing phenomenon of aggregation or fusion of liposomes in 
the bulk suspension. 
Indeed, liposomes also maintained their shape and size after 72 h of incubation in culture 
medium, suggesting that the presence of PEG2000 moieties on the surface of liposomes 
prevents the absorption of proteins in physiological environment. 
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Table 2- Stability of liposomes assessed by size measurement after 2 and 3 months of storage  
at 4°C 
Time (months) Mean Size (nm) (+/-SD) pdI 
0 113.1±37.4 0.08 
2 115.5±36.5 0.08 
3 111.9±37.0 0.08 
 
 
To assess whether the liposomes-based formulation of 6BrCaQ was able to retain the drug 
into the lipid bilayer in physiologic environment, the amount of drug released after 72 
and 120 h of incubation in culture medium was determined. 
After 72 h of incubation at 37°C, only 9.4% of the drug encapsulated was released from 
liposomes up to 37.95% after 120 h. These results confirmed that drug leakage is 
prevented when the bilayer becomes more fluid at physiologic temperature (T > Tm EPC). 
Therefore, the investigated liposomes resulted to be able to retain the drug for a time 
sufficient to deliver it into the cells, which occurs in a short time as demonstrated by 
confocal images (Figure 7). 
 
3.2. Biological activity in vitro 
 
Preliminary experiments established an IC50 (concentration which causes the death of 
50% of cells) of 10 µM for free 6BrCaQ for a time of treatment of 72 h for PC-3 cells 
(and about 5 µM for MDA-MB-231).  
The encapsulation of 6BrCaQ in liposomes allowed to reach the IC50 still at the 
concentration of 5 µM after 48 h treatment of MDA-MB 231 cells and any effect on cell 
viability was exerted by unloaded liposomes containing the same amount of lipids 
(Figure 3).  
In contrast, a weak toxicity of empty liposomes was found at the highest lipid 
concentration tested. This behavior was already observed for the same formulation in 
another breast cancer cell line [17, 19].   
The efficacy of liposomes was greater on prostate cancer cells. Indeed, 56.8 ± 5.8% of 
the treated cells died after 24 h of exposure at a concentration of 5 μM of drug 
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encapsulated and at the highest concentration tested (10 μM) the cell viability was almost 
double for free drug compared to liposomes (p= 5,53086E-05) (Figure 4). 
 
 
 
Figure 3-Metabolic activity of MDA-MB-231 cells (MTS assay) after 48 h exposure at 6BrCaQ 
free or liposomal (lipo (+)) at different concentrations (i.e. 1, 5 and 10 µM). Unloaded liposomes 
(lipo (-)) were used as controls. The reported data represent the mean of the metabolic activity of 
three different samples (three wells) for each condition tested. 
 
 
 
Figure 4- Metabolic activity of PC3 cells (MTS assay) after 24 h treatment with 6BrCaQ free 
(10µM) and 6BrCaQ liposomes (lipo (+)) (5 µM and 10 µM). Empty liposomes (lipo (-)) were 
used as controls. 
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The trend of the biological activity as a function of the time of exposure was evaluated in 
a kinetic study. For this purpose, cells were seeded in three different plates, exposed at 
time zero at the same treatment solution and analyzed after 24, 48 and 72 h of incubation. 
As previously observed, the effect of liposomes was anticipated compared to that of the 
free drug and also in that case the IC50 was found to be 5 µM and to be reached after only 
24 h of treatment. In contrast, the free drug resulted to be effective only at 10 µM and 
after 72 h treatment when loaded liposomes at the same concentration killed the totality 
of cells present in the well (Figure 5). PC3 cells resulted to be more sensitive with respect 
to MDA-MB 231 cells also to the exposure to empty liposomes for which a certain 
toxicity was observed (Figure 5). However, since the toxic effect didn’t increase with the 
time of treatment, it could be considered as an artifact of the in vitro test. This behavior 
may be explained by the variation of osmotic conditions that occurs in the cell 
environment as result of the addition of lipids along with a possible slight oxidation of 
unsaturated lipids, and may be exacerbated in vitro. The fact that this effect decreased 
with the time of exposure may mean that a certain period is required so that cells adapt to 
the changed surrounding. It should be underlined that also the toxicity of loaded 
liposomes at a concentration of 5µM resulted to be significantly higher (p < 0.01) after 
24 h of exposure whereas it remained almost constant for the next times of treatment. In 
fact, the effect of 5µM liposomes against PC3 cells was not found to be statistically 
different after 48 and 72 h treatment (p > 0.05). 
Altogether, the in vitro MTS results showed that the encapsulation of 6BrCaQ in 
liposomes improved the toxicity of the drug on breast and prostate cancer cells, enabling 
to reach a therapeutic efficacy at lower doses and for shorter time of treatment with 
respect to the free drug.  
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Figure 5- Trend of the metabolic activity of PC3 cells (MTS assay) after a) 24 h, b) 48 h and c) 
72 h treatment with 6BrCaQ free, loaded liposomes (lipo (+)) or empty liposomes (lipo (-)) at 
different concentrations 
 
 
To investigate whether the mechanism of action of 6BrCaQ remained unvaried after 
encapsulation in liposomes and to evaluate the effect on the proliferation and survival of 
prostate cancer cells, the distribution of cells in cell cycle was analyzed. 6BrCaQ, both in 
solution and encapsulated in liposomes, caused an arrest of cells in phase G2M and S 
with respect to the controls (Figure 6). After 72 h of exposure to the drug (free or 
encapsulated) an increase of the number of cells in phase S was observed compared to 
the controls (DMSO and unloaded liposomes), suggesting a potential induction of cell 
apoptosis through the inhibition of Hsp90 chaperone (Figure 6 b). This apoptosis can be 
induced from the cells blocked in G2/M phase. The internucleosomal degradation of 
DNA occurs from G2/M cells and then the DNA content is overlaying the DNA synthesis 
phase (4N DNA). Similar results were obtained in previous experiments on MDA-MB-
231 cell line (data not shown). 
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Figure 6-Cell cycle distribution of PC3 cells after: a) 24 h and b) 72 h of treatment with free or 
liposomal 6BrCaQ (5µM). DMSO and empty liposomes (lipo (-)) act as controls for free drug and 
loaded liposomes, respectively. 
 
 
 
3.3. In vitro liposome uptake 
 
The cellular uptake of liposomes was investigated by exposing MDA-MB-231 and PC-3 
cells to fluorescent liposomes (Figure 7). Any phenomenon of autofluorescence was 
observed for control cells. In contrast, when cells were treated with 6BrCaQ liposomes, 
an intense fluorescence was revealed in the cytoplasm and the signal resulted to be 
stronger close to the nucleus. 
The data confirmed that the improvement of the in vitro efficacy of 6BrCaQ encapsulated 
in liposomes was the result of a quick internalization of colloidal vesicles into the cells. 
Indeed, the presence of liposomes in the cytoplasm was observed already after 30 min of 
treatment in both cell lines (Figure 7). Hence, investigated liposomes were able to be 
uptaken into the target cells in short time and this behavior was responsible for the 
reduction of both effective dose and time of treatment with respect to the free molecule.  
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Figure 7-Confocal pictures of PC3 and MDA-MB-231 cells after treatment with fluorescent 
liposomes (Rho labeled) containing 6BrCaQ (5μM) 
 
 
 
3.4. Wound-healing assay 
 
Wound healing assay is a well-established method to study cell migration in vitro. When 
cell monolayers are scratched, the cell-cell contacts are destroyed and cells respond to the 
damage by increasing the production of growth factors to heal the wound [20].  
The migration of the cells during this healing process can be followed in vitro by using a 
video microscope. In our work, the assay was performed in presence of CCL2, also known 
as monocyte chemoattractant protein-1 (MCP-1), which is overexpressed in malignant 
prostate cancers [18]. In absence of treatment, prostate cells quickly migrated in the 
direction of the scratch and the wound resulted to be completely closed after 24 h (Figures 
8 and 9a). The cell motility instead was strongly inhibited when PC3 cells were treated 
with 20µM 6BrCaQ free (Figures 8 and 9b) or encapsulated in liposomes (Figures 8 
and 9d), confirming the ability of the drug to arrest the cell migration, contrasting the 
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chemotactic effect of CCL2. In another preliminary experiment, the efficacy of 6BrCaQ 
liposomes was compared to that of an inhibitor of CCL2 receptor (CCR2) used at an equal 
concentration (20µM) and the same degree of neutralization of CCL2 (40 ng/mL) 
invasion promoting effect was observed for the two drugs (data not shown). In contrast, 
the rate of migration resulted to be still high in the case of PC3 cells exposed to empty 
vesicles, as further proof that the efficacy of liposomes relied on the presence of 6BrCaQ 
(Figure 8). Indeed, the number of cells migrated per mm2 in the well of control (DMSO) 
and in that of empty liposomes was not found to be statistically different (p > 0.05). 
Recent studies revealed that Hsp90 enhances cell migration binding the CD91 receptor 
expressed on the cell surface and that the block of Hsp90 activity inhibits the formation 
of metastasis in vivo [21]. In this study it was confirmed that using an inhibitor of the C-
terminal domain of Hsp90, it is possible to slow down the migration of prostate cancer 
cells in vitro, thus contrasting their high metastatic potential.  
   
 
 
Figure 8- Rate of migration of PC3 cells during wound healing assay. Effect of 6BrCaQ free and 
liposomal (20 µM) in presence of chemokine CCL2 (40 ng/mL). DMSO and empty liposomes 
(lipo (-)) were used as controls. The number of cells migrated at each time in a ROI selected 
within the edges of the scratch is plotted as a function of time. 
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              t=0 h                            t=24 h                             t=0 h                            t=24 h 
 
 
 
Figure 9- Representative images of PC3 cells migration in the direction of the wound when 
exposed to: a) DMSO; b) free drug (20 µM); c) empty liposomes (at the same lipid 
concentration of loaded ones); d) 6BrCaQ liposomes (20 µM). Chemokine CCL2 at a 
concentration of 40 ng/mL was present in each well. For each treatment condition, representative 
pictures of the well taken at t=0 h and t= 24 h are shown. 
 
 
 
 
4. Conclusions 
 
In this work Stealth® nanoliposomes have been developed and used as carriers for the 
administration of an hydrophobic inhibitor of Hsp90 chaperone, 6BrCaQ. The formulated 
liposomes had the desired nano-sized dimensions and resulted to be stable both in bulk 
and culture conditions. The quickly intracellular uptake of the nanocarriers (30 minutes) 
allowed the liposomes to potentiate the effect of the free drug halving the IC50 on both 
prostate and breast cancer cells and decreasing the time of treatment required. It was then 
confirmed the suitability of Stealth® nanoliposomes as carriers to target cancer. 
Moreover, 6BrCaQ encapsulated in liposomes inhibited the proliferation of prostate 
cancer cells causing an arrest of the cell cycle in G2/M phase. The drug was also able to 
contrast the chemotactic action of CCL2 slowing down the cell migration in vitro. This 
effect makes 6BrCaQ liposomes a promising tool to be exploited to prevent the formation 
of metastasis, mainly in bones, which is the major cause of the poor prognosis of this type 
of cancer. 
a) b) 
c) d) 
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Altogether, the experimental data confirmed the efficacy of 6BrCaQ to exert anticancer 
activity through the inhibition of Hsp90 chaperone and the suitability of liposomes as 
proper vehicles for the administration of this hydrophobic drug in vivo.   
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